University of Rhode Island

DigitalCommons@URI
Open Access Dissertations
2018

In Vitro Drug Metabolism and Population Pharmacokinetics as
Tools for Elucidating Pharmacokinetic Variability
Enoch Cobbina
University of Rhode Island, libaws777@yahoo.co.uk

Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss

Recommended Citation
Cobbina, Enoch, "In Vitro Drug Metabolism and Population Pharmacokinetics as Tools for Elucidating
Pharmacokinetic Variability" (2018). Open Access Dissertations. Paper 725.
https://digitalcommons.uri.edu/oa_diss/725

This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.

IN VITRO DRUG METABOLISM AND POPULATION
PHARMACOKINETICS AS TOOLS FOR
ELUCIDATING PHARMACOKINETIC VARIABILITY

BY
ENOCH COBBINA

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY
IN
PHARMACEUTICAL SCIENCES

UNIVERSITY OF RHODE ISLAND
2018

DOCTOR OF PHILOSOPHY DISSERTATION

OF

ENOCH COBBINA

APPROVED:
Dissertation Committee:
Major Professor

Fatemeh Akhlaghi
Sara Rosenbaum
Prabhani Kuruppumullage Don

Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2018

ABSTRACT
Pharmacokinetic variability is an important consideration in pharmacotherapy to
ensure safety and efficacy of medications, thus the understanding of the sources of
variability in drug concentrations in the body is imperative.

The goals of this

dissertation were: (1) To use in vitro drug metabolism tools to characterize the
influence of non-alcoholic fatty liver disease (NAFLD) on Cytochrome P450 2B6
(CYP2B6)-mediated hydroxylation of bupropion in human liver microsomes; and (2)
To use population pharmacokinetics to characterize the pharmacokinetics of PF5190457, an inverse agonist of the growth hormone secretagogue receptor (hGHSR1a). This work has been organized in two parts. Part one is made up of manuscripts
I-III; and addresses the first objective. Part two, on the other hand, is made up of
manuscript IV, and addresses the second objective.

The manuscripts are briefly

described below:
Manuscript I: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver
disorders. It is defined by the presence of steatosis in more than 5 % of hepatocytes
with little or no alcohol consumption. The physiological and biochemical changes
associated with NAFLD may result in altered expression and activity of drug
metabolizing enzymes (DMEs) or transporters. Existing evidence suggests that the
effect of NAFLD on CYP3A4, CYP2E1 and MRP3 are more consistent across rodent
and human studies. CYP3A4 activity is down-regulated in NASH whereas the activity
of CYP2E1 and the efflux transporter MRP3 are up-regulated. However, it is not clear
how the majority of CYPs, UGTs, SULTs and transporters are influenced by NAFLD

either in vivo or in vitro. The alterations associated with NAFLD could be a potential
source of drug variability in patients and could have serious implications for the safety
and efficacy of xenobiotics.

In the first manuscript, we reviewed the effects of

NAFLD on the regulation, expression and activity of major drug metabolizing
enzymes and transporters. We also discussed the potential mechanisms underlying
these alterations.
Manuscript II: Diabetes is strongly associated with NAFLD. However, tools for
predicting the diabetic status of human liver tissues (HLTs) is lacking. Manuscript II
was aimed to establish a model-based approach for predicting the diabetic status of
donors of HLTs.

The liver tissue as well as demographic and anthropometric

information were supplied by Xenotech LLC. Histopathological examination was
conducted to characterize NAFLD lesions. HLTs were homogenized and levels of
feeding-related hepatic neuroendocrine peptides (active amylin, insulin, c-peptide,
glucagon, ghrelin, active GLP-1, GIP, PP, PYY, leptin and MCP-1) determined. The
association between diabetes, and these covariates was modeled using multiple logistic
regression. The statistically validated model was used to predict new diabetic classes
of HLTs. A multiple logistic regression model adequately described the association
between diabetes, NAFLD lesions and the neuroendocrine peptides. Liver weight, cpeptide, leptin, PYY, Amylin (active) and steatosis were significant predictors of
diabetes. The final model had an AROC curve of 0.89, accuracy of 80%, sensitivity of
82.4% and specificity of 77%. The new diabetic classes showed that hepatic GLP-1
(active) level was 1.4 higher in non-diabetic livers compared to diabetic ones. In
addition, the logistic regression model can be used as a tool to verify the diabetic

status of HLTs which are used for drug metabolism studies.

Manuscript III: Despite the initial belief that Cytochrome P450 (CYP) 2B6 is of
minor significance, it is now recognized as a clinically relevant drug metabolizing
enzyme.

The impact of non-alcoholic fatty liver disease (NAFLD) on drug

metabolism has been identified; however, it is still unclear how it influences CYP2B6.
We used in vitro approaches in human liver microsomes (HLM) and HepaRG cells to
investigate

the

effect

of

NAFLD

on

CYP2B6-mediated

formation

of

hydroxybupropion. The presence of NAFLD increased the km significantly (p < 0.04)
and reduced CYP2B6 intrinsic clearance by 2-fold. The results from the HepaRG
cells qualitatively recapitulated findings in the HLMs. Fatty acid accumulation in
hepatocytes seems to be involved with the alteration. This investigation contributes to
our current knowledge on the influence of NAFLD on CYP2B6 in vitro kinetics and
offers a basis for clinical trial in this patient population.

Manuscript IV:

PF-5190457 is an inverse agonist of the growth hormone

secretagogue receptor (hGHS-R1a), that is undergoing clinical trial for treatment of
alcohol use disorder.

The purpose of this study was to describe the population

pharmacokinetics (PK) of PF-5190457 and to identify demographic and biochemical
characteristics that influence its PK variability. Data on drug dosage, sampling times
and plasma concentrations were collected retrospectively from two studies: Phase 1a
and Phase 1b. Thirty five (35) healthy volunteers were enrolled in the Phase 1a, and
12 non-treatment seeking alcoholic subjects in the Phase 1b trial. The log-transformed
concentration and time points were modeled in NONMEM. The influence of patients'

demographic and biochemical characteristics were evaluated; and the accuracy and
precision of the model parameters determined using bootstrapping. The predictive
performance of the final model was checked using percentile visual predictive checks.
The pharmacokinetics of PF-5190457 was best described by a one-compartmental
model with first order absorption after oral administration. The estimated typical
pharmacokinetic parameters included the absorption rate constant (ka, 3.6 h-1), oral
clearance (CL/F, 80 Lh-1) and apparent volume of distribution (V/F, 575 L). Inclusion
of body weight and serum albumin as covariates on V/F reduced the interindividual
variability (IIV) associated with V/F by ~28%. Increasing body weight increased V/F,
whereas increasing serum albumin levels reduced it. We anticipate that this model
would serve as a guide in designing dosage regimen for future clinical trials with PF5190457.
Conclusion. This work demonstrates that in vitro drug metabolism in human liver
microsome has the potential to explain the effect of NAFLD on CYP2B6-mediated
hydroxybupropion formation.

Similarly, population pharmacokinetic modeling in

NONMEM has the capability to elucidate the influence of body weight and serum
albumin on the pharmacokinetics of PF-5190457.
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PREFACE
This dissertation titled “In Vitro Drug Metabolism and Population Pharmacokinetics
as Tools for Elucidating Pharmacokinetic Variability” is presented in manuscript
format.
The first chapter is an introduction of general concepts in Pharmacokinetics and
Pharmacokinetic variability. The next four chapters (2-5) are four manuscripts.
Manuscript I was published in Drug Metabolism Review (Drug Metab Rev. 2017
May;49(2):197-211). Manuscript II has been formatted for publication in
Diabetes/Metabolism Research and Reviews Journal. Manuscript III has been
prepared for submission to Diabetes, Obesity and Metabolism Journal. Finally,
Manuscript IV has been prepared for submission to Clinical Pharmacokinetics
Journal.
In all four manuscripts, Dr. Fatemeh Akhlaghi, my major Professor is the
corresponding author. Any other contributors have been included as co-authors or
acknowledged appropriately.
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BACKGROUND

Introduction
Pharmacokinetics is the study of the processes involved with the absorption (A),
distribution (D), metabolism (M) and excretion (E) of drugs from the body. Thus, the
body interacts with the drug to absorb it from the site of administration and transport
to the site of action to exert its effect before it is finally removed from the body. The
ADME processes control the concentration a drug achieves in body compartments
after administration of a dose. This implies that changes in the ADME properties can
alter pharmacokinetic properties of a drug and ultimately the efficacy and toxicity. To
improve the safety and efficacy of drugs, the sources of pharmacokinetic variability
must be characterized and applied to individualize dosing.

Pharmacokinetic

variability results from inter-individual differences that alter pharmacokinetic
parameters that control absorption, distribution, metabolism and excretion.

Absorption.
Drugs administered by extravascular route, are absorbed into the systemic circulation.
Some drugs may undergo first pass metabolism in the enterocytes of the small
intestines and the liver before they finally reach the systemic circulation. The product
of the fraction of the drug that is absorbed into the enterocytes (fa), the fraction that
escapes metabolism in the enterocyte (fg) and the fraction that escapes first-pass
hepatic metabolism (fh) is described by the bioavailability parameter, F.
F = fa*fg*fh ................................................(1)
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The rate of absorption of a drug usually follows a first-order kinetics. The important
pharmacokinetic parameters of absorption are the absorption rate constant (ka) and the
overall bioavailability. The absorption of a drug in the GIT may be affected by the
motility of the GIT, pH changes, presence of food, concomitant medication, and
transporters. Consequently, these conditions can alter the magnitude of ka and the
bioavailability (Rosenbaum, 2011).

Distribution.
The apparent volume of distribution (Vd) is the pharmacokinetic parameter that
quantitatively describes the distribution of a drug in the body. It is the ratio of the
amount of drug in the body at equilibrium (Ab) and the drug plasma concentration
(Cp). Though this parameter does not have a physiological significance, it gives a
general idea about the extent of drug distribution in the body. The extent of the
distribution of a drug depends on tissue binding and plasma protein binding. The
magnitude of Vd depends on whether the drug binds strongly to the plasma proteins or
to tissues. A high plasma protein binding may result in a small Vd, whereas a high
tissue binding may yield a large Vd.
The rate of drug distribution on the other hand, depends on tissue perfusion and
diffusion into cells. Drug distribution is faster in well-perfused tissues than in poorlyperfused ones. In addition, small lipophilic drugs are able to distribute into tissues
faster through passive transcellular diffusion. It must also be borne in mind that
transporters like p-gp, MRP4 and BCRP play some role in drug distribution (Urquhart
and Kim, 2009). The extent of drug distribution is affected by conditions that affect

2

blood and tissue volume as well as the free fraction of drug in the plasma and tissues.
It is anticipated that since tissue-perfusion and diffusion control the rate of
distribution, conditions that affect perfusion and diffusion would also affect the rate of
distribution.

Elimination.
Drugs are eliminated from the body through metabolism and excretion. The primary
organ for metabolism is the liver, whereas the kidney is the cardinal organ for
excretion. Metabolism is a process whereby drug molecules are biotransformed into
their metabolites by addition of groups that make them more hydrophilic. Drug
metabolizing enzymes (cytochrome P450 enzyme, flavin monooxygenase, and UDPglucuronosyltransferases (UGTs)) and transporters (MRPs, OATPs etc) are involved
in the metabolism of drugs.
Renal excretion results from glomerular filtration, active tubular secretion and passive
tubular reabsorption. The capillaries of the glomerulus are very permeable and allows
neutral molecules of less than 4 nm diameter to pass through into the renal tubules.
The presence of transporters in the proximal tubular cells augment renal clearance
through tubular secretion (Ho and Kim, 2005, Kusuhara, 2009, Choi and Song, 2008).
The uptake transporters involved in this process include OAT1, OAT3 and OCT2
whereas the efflux transporters include P-gp, MRP2 and MRP4. At the distal tubule,
drugs may be reabsorbed through passive diffusion depending on the lipophilicity, pH
of the filtrate and the flow of the urine.
Elimination incorporates the processes of metabolism and excretion. The elimination
3

of most drugs follow first order kinetics. The constant of proportionality between the
rate of elimination and the plasma concentration is called clearance. Clearance is the
most important pharmacokinetic parameter and it is defined as the volume of blood
that is completely cleared of the drug per unit time. It is a function of blood flow and
the efficiency with which the organs of elimination extract the drug that passes
through them. Hence, conditions that affect these organs and their function like
diseases affect the clearance and eventually the pharmacokinetics of the drug.

The elimination half-life of a drug.
The ratio of the clearance (Cl) and the volume of distribution (Vd) is called the
elimination rate constant (ke). Closely related to the elimination rate constant is the
half-life of a drug. It is the time required for the amount of drug in the body to fall by
half, and it is estimated as:
t1/2 = 0.693/ke ......................................................(2)
The elimination rate constant and the half-life are derived parameters and depend on
the volume of distribution and clearance which are independent of each other.
The half-life of a drug is particularly important because it helps to determine the time
it takes a drug to reach steady state. It also guides the selection of dosing interval in
multiple dosing. Since t1/2 depends on clearance and volume of distribution, any factor
that alters the distribution or clearance of a drug may alter its half-life. This would
alter the dosing interval, the time to reach steady state and the time it will take to clear
the drug from the body.

4

Elucidating the sources of pharmacokinetic variability.
To understand the sources of pharmacokinetic variability, pharmacokinetic parameters
are investigated under various conditions to elucidate how those conditions influence
their magnitude.

These conditions include food, gender, lifestyle, genetic

polymorphisms, diseases and co-administered drugs.
In this work, two methodologies were employed to investigate pathological and nonpathological sources of PK variability. In the first part of the study (manuscripts I, II
and III), the influence of non-alcoholic fatty liver disease was investigated in vitro
using both human liver microsomes (HLM) and steatosis-induced HepaRG cell lines.
By incubating each of the two in vitro systems with a CYP2B6 probe substrate,
bupropion, we were able to estimate parameters related to the in vitro clearance of
bupropion via the CYP2B6 drug metabolizing enzyme pathway.

Comparing the

values obtained among the control and treatment groups enabled us to establish the
influence of NAFLD on CYP2B6-mediated clearance of bupropion. NAFLD was
chosen as the disease of interest mainly because it affects the liver, the major organ of
clearance; and also because NAFLD is prevalent in the population.
In the second part of the study (manuscript IV), population pharmacokinetics using
nonlinear mixed effect modeling was employed to determine the pharmacokinetic
parameters of a ghrelin inverse agonist, PF-5190457, administered to healthy and nontreatment seeking alcoholic adults. The influence of various covariates including
demographic (age, BMI, and Gender, etc.), and biochemical (albumin, serum
creatinine, etc.) variables were examined on the pharmacokinetic parameters - ka, CL
and Vd.
5

By employing these two methodologies, we were able to demonstrate the effect of
NAFLD on CYP2B6-mediated formation of hydroxybupropion and the factors that
influence the disposition of PF-5190457.
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MANUSCRIPT I

Abstract
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is
defined by the presence of steatosis in more than 5 % of hepatocytes with little or no
alcohol consumption. Insulin resistance, the metabolic syndrome or type 2 diabetes
and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of
NAFLD. The pathological progression of NAFLD follows tentatively a ‘three-hit’
process namely steatosis, lipotoxicity and inflammation. The presence of steatosis,
oxidative stress and inflammatory mediators like TNF-α and IL-6 have been
implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in
NAFLD. These factors may result in altered expression and activity of drug
metabolizing enzymes (DMEs) or transporters.
Existing evidence suggests that the effect of NAFLD on CYP3A4, CYP2E1 and
MRP3 are more consistent across rodent and human studies. CYP3A4 activity is
down-regulated in NASH whereas the activity of CYP2E1 and the efflux transporter
MRP3 are up-regulated. However, it is not clear how the majority of CYPs, UGTs,
SULTs and transporters are influenced by NAFLD either in vivo or in vitro. The
alterations associated with NAFLD could be a potential source of pharmacokinetic
variability in patients and could have serious implications for the safety and efficacy
of xenobiotics. In this manuscript, we summarize the effects of NAFLD on the
regulation, expression and activity of major drug metabolizing enzymes and
transporters. We also discuss the potential mechanisms underlying these alterations.
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1.1 Introduction
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders (Figure
1.1). It is a condition defined by the presence of steatosis in more than 5 % of
hepatocytes (Sanyal et al., 2011) with little or no alcohol consumption. NAFLD
consists of the benign non-alcoholic fatty liver (NAFL), and the more severe nonalcoholic steatohepatitis (NASH). NASH is a more progressive form of NAFLD and
is characterized by steatosis, hepatocellular ballooning, lobular inflammation and
almost always fibrosis (Kleiner and Makhlouf, 2016). In an effort to regenerate new
cells, NASH progresses (Argo and Caldwell, 2009, Starley et al., 2010) to cirrhosis
with the hepatocytes replaced by scar tissues of type I collagen produced by stellate
cells. Cirrhosis is an end stage organ failure that require liver transplantation or may
lead to hepatocellular carcinoma (Sorensen et al., 2003, Yasui et al., 2011). With
progression of NASH to full-blown cirrhosis, some of the histological characteristics
of NASH might be lost (Yoshioka et al., 2004).
The metabolic syndrome, formerly known as Syndrome X, underlies both nonalcoholic fatty liver disease (NAFLD) and diabetes. It is defined by the presence of at
least three of the following (Figure 1.2): abdominal obesity, increased triglycerides,
reduced high density lipoprotein (HDL) cholesterol, increased blood pressure and
hyperglycemia (Alberti et al., 2009). Insulin resistance appears to explain almost all
situations of metabolic syndrome (Eckel et al., 2010); and hence diabetes (Groop,
1999) and NAFLD (Marchesini et al., 1999).
Though NAFLD is more prevalent in obese and diabetic patients, it is also present in
lean and non-diabetic individuals (Vos et al., 2011, Younossi et al., 2012). It is the
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most common cause of cryptogenic cirrhosis (Clark and Diehl, 2003) and
approximately 30 -50 % of NASH patients may progress to cirrhosis within 10 years
(Jou et al., 2008). NAFLD is not only prevalent in industrialized countries, but also in
developing ones. Global prevalence of NAFLD has been reviewed and ranges from 6
- 35 % (Fazel et al., 2016, Sayiner et al., 2016, Bellentani, 2017); and approximately
30% of the population of United States (90 million persons) are estimated to be
affected by NAFLD (Fazel et al., 2016). About 70% Americans with diagnosed type
2 diabetes are believed to have NAFLD while 63–87% of patients having both
diabetes and NAFLD may have NASH. (Bazick et al., 2015, Corey et al., 2016). The
economic burden of NAFLD in four European countries (Germany, France, Italy and
the United Kingdom) was projected to be ~35 billion US dollars compared to the
approximately 103 billion dollars in the United States (Younossi et al., 2016).
Pharmacotherapy of NAFLD or NASH is an unmet clinical need. To date, no drug
has received FDA approval for NASH (Sanyal et al., 2015), thus a clinical or
regulatory pathway has not yet been established. Current therapies like vitamin E
(Rinella and Sanyal, 2016), pentoxifylline (Zein et al., 2011) and insulin sensitizers
such as pioglitazone in patients with diabetes (Cusi, 2016) have been used. Therapies
in development include obeticholic acid, a semi-synthetic bile acid analogue
undergoing development by Intercept Pharmaceuticals and elafibranor (formerly
GFT505) a Peroxisome proliferator-activated receptor (PPAR) alpha and gamma
agonist (Rinella and Sanyal, 2016).

In view of the lack of standard therapy,

international guidelines on NAFLD (European Association for the Study of the Liver
(EASL), 2016) recommend lifestyle modifications particularly diet and exercise as
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treatment options.

Recently, the role of Mediterranean diet in prevention and

treatment of NAFLD has been proposed (Abenavoli et al., 2014, Godos et al., 2017).
The main clearance mechanisms of xenobiotics from the body are hepatic, renal and
biliary. It has been reported that more than 60 % of commonly prescribed drugs in the
United States are cleared hepatically (Williams et al., 2004), indicating the crucial role
of the liver in drug metabolism. Hepatic clearance of drugs is achieved through the
activities of drug metabolizing enzymes (DMEs) and transporters and hence factors
that affect their regulation and activities eventually alter drug disposition.
In this manuscript, we summarize the effects of NAFLD on the regulation, expression
and activity of major drug metabolizing enzymes and transporters. In addition, we
discuss the various classification systems of NAFLD and the potential mechanisms
underlying these alterations. This work however does not include a discussion on
models of NAFLD and most findings published before 2011 since these have been
reviewed by other groups (Merrell and Cherrington, 2011, Naik et al., 2013).

1.2 Pathogenesis of NAFLD
The mechanisms leading to NAFLD is unclear to date. Several mechanisms have
been proposed, but insulin resistance seems to be pivotal in the pathogenesis of both
NAFLD and type 2 diabetes (Shulman, 2000, Tarantino and Finelli, 2013). The
genetic variant of PNPLA3 (patatin-like phospholipase domain-containing protein 3),
an enzyme encoding I148M (rs738409 C/G) and involved in the hydrolysis of
triacylglycerols in adipocytes, has been reported to be associated with NAFLD
13

independent of the metabolic syndrome (Romeo et al., 2008, Sookoian and Pirola,
2011).

Similarly, the genetic variant of the lipid transporter located on ER

(endoplasmic reticulum) and ER-Golgi compartments, TM6SF2 (transmembrane 6
superfamily member 2), encoding E167K (rs58542926 C/T), causes loss of function of
the protein and increases hepatic deposition of triglycerides (Dongiovanni et al.,
2015).

The pathological progression of NAFLD follows tentatively a ‘three-hit’

process (Jou et al., 2008) namely steatosis, lipotoxicity and inflammation.
Steatosis results from the interplay between diet, gut microbiota (Jiang et al., 2015,
Kirpich et al., 2015), genetic factors (Romeo et al., 2008), and de novo lipogenesis via
up-regulation of lipogenic transcription factors like sterol regulatory binding protein1c (SREBP1c), carbohydrate-responsive element-binding protein (chREBP), and
peroxisome proliferator-activated receptor gamma (PPAR-γ) (Anderson and Borlak,
2008).

Primarily, fatty acid (FA) is stored in the adipose tissue as TAG

(triacylglycerol). However, in obese subjects, fatty acids seem to be misrouted from
their primary storage site to ectopic sites like skeletal and hepatic tissues for reesterification into diacyl glycerols (DAGs), perhaps through increased adipocyte
lipolysis. The uptake of fatty acid by these organs probably is facilitated by fatty acid
transport proteins (FATPs) and FAT/CD36 (fatty acid translocase) which have been
shown to be elevated in obese subjects and NAFLD patients (Greco et al., 2008,
Fabbrini et al., 2009).
Steatosis leads to increased signaling of the transcription factor NF-κβ (nuclear factor
– kappaβ) through the upstream activation of IKKβ (inhibitor of nuclear factor kappaB
(NF-κB)).

The activation of NF-κβ induces the production of pro-inflammatory
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mediators like TNF-α (tumor necrosis factor - alpha), IL-6 (interleukin-6) and IL-1β
(interleukin-1 β). These cytokines contribute to the recruitment and activation of
Kupffer cells (resident hepatic macrophages) (Anderson and Borlak, 2008) to mediate
inflammation in NASH (Ramadori and Armbrust, 2001, Joshi-Barve et al., 2007).
Additionally, TNF- α and IL-6 have been reported to play a role in hepatic insulin
resistance through the up-regulation of SOCS3 (suppressor of cytokine signaling 3)
(Persico et al., 2007, Torisu et al., 2007).
The excess fat in the liver causes lipotoxicity and leads to organelle failure mainly
mitochondrial dysfunction and endoplasmic reticulum stress (Browning and Horton,
2004, Bell et al., 2008 ). A dysfunctional mitochondrion has an elevated capacity to
oxidize FA resulting in the production of ROS (reactive oxygen species) and causing
oxidative stress due to an imbalance between the production of ROS and protective
oxidants. Oxidative stress in NAFLD patients (Sanyal et al., 2001, Tiniakos et al.,
2010) is regarded as the third insult that eventually leads to hepatocyte death. The
pathogenesis of NAFLD seem to be a vicious cycle of steatosis, lipotoxicity and
inflammation resulting in intricate alterations in the histopathological and biochemical
features of the liver.

1.3 Diagnosis and Classification of NAFLD
The diagnosis of NAFLD is challenging, as the current available routine techniques
(serological tests and imaging techniques) are unable to distinguish between steatosis
and NASH. Liver biopsy is considered the gold standard in defining NAFLD and is
capable of differentiating steatosis and NASH. It is however, not recommended for
routine use due to increased risk of bleeding and complications. In the last decades,
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many diagnostic non-invasive tools have been described (Table 1.1).

Accurate

diagnosis of NAFLD is important for its classification. Some of the classification
systems available include the scoring systems by Matteoni (Matteoni et al., 1999 ),
Brunt (Brunt et al., 1999), NASH CRN (Clinical Research Network) system (Kleiner
et al., 2005), and the SAF (steatosis, activity and fibrosis) system (Bedossa et al.,
2012). The different classification systems of NAFLD may thus yield different results
and hence introduce variability into scientific investigations.
One of the pioneering works with the largest number of patients and longest follow-up
for the stratification of NAFLD patients was carried out (Matteoni et al., 1999 ). The
Matteoni's system was based on fat accumulation, inflammation, ballooning
degeneration, Mallory hyaline and fibrosis.

NAFLD patients were put into four

groups: Type I (simple fatty liver), Type II (steatohepatitis), Type III (steatonecrosis)
and Type IV (steanecrosis plus either Mallory hyaline or fibrosis).

Type I was

relatively benign whereas the necrotic forms were considered aggressive.

The

aggressive forms have higher risk of cirrhosis and liver-related death. Though this
system helps to identify patients at risk of cirrhosis and liver-related death, it does not
take into account NAFLD in children.
The system developed by Brunt (Brunt et al., 1999, Brunt et al., 2004) is semiquantitative and evaluates the unique lesions of NASH.

It unifies steatosis and

steatohepatitis into a ‘grade’ and fibrosis into a ‘stage’(Angulo, 2002). Steatosis is
graded on a scale of 1 to 3 depending on the percentage of hepatocytes affected (<33%
=1; 33-66% = 2; >66% = 3). Steatohepatitis was similarly graded on a scale of 1 to 3
(1 = mild; 2 = moderate; 3 = severe) but based on the severity and extent of steatosis,
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ballooning, lobular inflammation and portal inflammation. Fibrosis on the other hand
was staged on a scale of 1 to 4. Brunt’s system does not cover the entire spectrum of
NAFLD as defined by Matteoni's system.

Additionally, it was not designed to

evaluate NAFLD in children (Kleiner et al., 2005).
In 2005, the Pathology Committee of the NASH Clinical Research Network (NASH
CRN) of the National Institute of Diabetes & Digestive & Kidney Disease (NIDDK)
came up with a scoring system and NAFLD activity score (NAS) for use in clinical
trial (Kleiner et al., 2005). The scoring system was intended to address the full
spectrum of lesions of NAFLD. The histological features considered were grouped
into five broad categories each with a scoring scale. These features, which were
independently associated with NASH, included steatosis (0-3), lobular inflammation
(0-3), hepatocellular injury (0-2), fibrosis (0-4) and miscellaneous features like
Mallory’s hyaline and glycogenated nuclei. The NAS is the unweighted sum of
steatosis, lobular inﬂammation, and hepatocellular ballooning scores. NAS of ≥ 5 was
found to correlate with the diagnosis of NASH and biopsies with scores of less than 3
were classified as “not NASH”. Notwithstanding, not all biopsies with NAS ≥ 5 meet
the diagnostic criteria of definite NASH and should be used carefully in establishing
the presence or absence of NASH (Brunt et al., 2011). In a number of experimental
work involving humans and rodents, a NAS score of at least 4 was considered as
NASH (Canet et al., 2014, Ferslew et al., 2015).
Recently, the SAF (steatosis, activity and fibrosis) system has been proposed. The
SAF considers steatosis, lobular inflammation and ballooning in defining NAFL and
NASH. The activity is defined as the sum of the grades of lobular inflammation and
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ballooning and ranges from 0-4. The presence of NAFLD is defined by steatosis in
the presence of any degree of activity. This implies that the definition of either NAFL
or NASH requires the presence of steatosis (1-3) and varying degree of activity
(NAFL: steatosis (1-3) + lobular inflammation (0) + ballooning (0-2), or steatosis (13) + lobular inflammation (1-2) + ballooning (0); and NASH: steatosis (1-3) +
lobular inflammation (1) + ballooning (1-2) or steatosis (1-3) + lobular inflammation
(2) + ballooning (1-2)) (Bedossa et al., 2012, Kleiner and Makhlouf, 2016).
Clinicobiological scores have also been used in relation to NAFLD for several reasons
including selection of patients needing biopsy and prediction of advanced forms of
NASH. These clinicobiologial scores make use of indices like body mass index
(BMI), Age, AST/ALT ratio, albumin, platelet count, diabetes, hyperglycemia, insulin
resistance index, triglycerides, hypertension and others (Angulo et al., 1999, Dixon et
al., 2001, Harrison et al., 2003). For instance, ‘BAAT’ scoring (Ratziu et al., 2000 )
uses BMI, age, ALT, and serum triglycerides. The BAAT score is calculated as the
sum of categorical variables with a scale of 0 to 4. A score of 0 or 1 on the BAAT
scale would indicate absence of septal fibrosis. ‘HAIR’ scoring (Dixon et al., 2001)
on the other hand utilizes hypertension, ALT and insulin resistance as an index with a
scale of 0 to 3. A score of ≥2 is suggestive of NASH.

1.4 Mechanisms of the alteration of DMEs and Transporters in
NAFLD
The influence of diseases on DMEs and transporters is complex due to the associated
physiological and pathological changes. For instance, inflammatory conditions have
been reported to cause the release of circulating pro-inflammatory cytokines like TNF18

α, IL-1β, and IL-6 which act as signaling molecules to mediate the down-regulation of
drug metabolizing enzymes partly through the suppression of transcription (Aitken et
al., 2006, Aitken and Morgan, 2007).

The inflammation models, bacteria

endotoxemia (lipopolysaccharide (LPS)) and turpentine have been employed in
rodents and hepatocytes to gain some insight into the role of cytokines on the
regulation of DMEs and transporters. It seems that in majority of cases, inflammation
and the associated cytokines down-regulate the expression and activity of DMEs and
some transporters as described in these reviews (Aitken et al., 2006, Morgan, 2009).
Oxidative stress in NAFLD and diabetes causes activation of Nrf2 (nuclear factor
erythroid 2-related factor 2) in both experimental (Fisher et al., 2008) and clinical
studies (Hardwick et al., 2010). Nrf2 is a specific transcription factor that controls the
antioxidant response. It is released from keapl (Kelch-like ECH-associated protein 1)
and is translocated to the nucleus where it binds to antioxidant response element
(ARE) within promoters of target genes, and induces expression of DMEs and
transporters central to the maintenance of oxidative stress inducing molecules
(Jaiswal, 2004, Nakata et al., 2006, Zhang, 2006).
Fatty acids regulate gene expression by controlling the activity or expression of key
nuclear receptors.

In vitro studies have identified many transcription factors as

possible targets for fatty acid regulation, including hepatic nuclear factors (HNF-4α
and γ), PPARα, β, γ1, and γ2, SREBP-1c, retinoid X receptor (RXRα), liver X
receptor (LXRα), and others. Some nuclear receptors, PPAR, HNF4 (hepatic nuclear
factor), RXRα, and LXRα, bind directly to non-esterified fatty acids (NEFA), but
others like SREBP-1c and NF-κB are regulated by fatty acids through indirect
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mechanisms (Jump et al., 2005, Jump, 2008). In rodents, SREBP-1c inhibits PXR
(pregnane X receptor) and CAR (constitutive androstane receptor) (Roth et al., 2008),
and has been shown to be up-regulated in obese insulin-resistant patients (Pettinelli et
al., 2009). The modulation of the activity of CAR and PXR by polyunsaturated fatty
acids (PUFA) has also been reported (Finn et al., 2009).
In addition, changes in the architecture of the liver in hepatic cirrhosis have been
reported to cause reduced liver blood flow, reduced functional hepatocytes and
diminished functional capacity of the liver to synthesize serum proteins including
albumin (Elbekai et al., 2004, Edginton and Willmann, 2008, Johnson et al., 2010).
Collectively, the changes mediated by excess fatty acids, cytokines, oxidative stress,
and other mechanisms in NAFLD and diabetes may affect the hepatic metabolism of
certain drugs possibly through the alteration of the expression and activity of DMEs
and transporters.

This could result from host defense mechanisms at the

transcriptional as well as pre- and post-translational levels (George et al., 1995,
Renton, 2004, Aitken et al., 2006). These aberrant signals disrupt the normal hepatic
signaling pathways and eventually dysregulate major drug-metabolism-associated
nuclear factors leading to altered drug metabolism in NAFLD and diabetic patients
(Naik et al., 2013).

1.5 Hepatic Drug Metabolism
Phase I reactions are mainly oxidative processes and are predominantly carried out by
the cytochrome P450 (CYP) enzyme system (Guengerich and MacDonald, 1990,
Guengerich, 2008, Guengerich and Munro, 2013). Of the 18 known families of CYP
enzymes (Zanger and Schwab, 2013), only a few of the members belonging to families
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1, 2 and 3 appear to be relevant to biotransformation of xenobiotics (Cholerton et al.,
1992, Zanger and Schwab, 2013).

These include CYP1A1, CYP1A2, CYP2A6,

CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, and
CYP3A5.

Non-CYP enzymes involved in phase I reactions include monoamine

oxidase, flavin-containing monooxygenase (Rettie et al., 1995, Fisher et al., 2002) and
aldehyde oxidase (Johns, 1967 ).
Phase II biotransformation on the other hand are primarily conjugation reactions and it
includes glucuronidation (Meech and Mackenzie, 1997), sulfation (Negishi et al.,
2001), and glutathione conjugation (Sofia et al., 1997). The enzymes responsible for
these processes are Uridine diphosphate (UDP) - glucuronosyl transferases (UGTs),
Sulfotransferases (SULT1A), Glutathione -S-transferases (GSTs) respectively.
Drug transporters are crucial for metabolism of drugs and have been reviewed by
several groups (Giacomini et al., 2010). Hepatic transporters are classified into uptake
and efflux transporters (Mizuno and Sugiyama, 2002, Mizuno et al., 2003). The main
uptake transporters belong to the solute carrier (SLC) superfamily and facilitate the
movement of drugs into cells. These include OATPs (organic anion transporting
polypeptides), OCTs (organic cation transporter), and OATs (organic anion
transporter). The efflux transporters on the other hand belong to the ABC (ATPbinding cassette) superfamily and help move drugs out of cells (Mizuno et al., 2003,
Sugiura et al., 2006). Examples include P-gp (P-glycoprotein), BCRP (Breast cancer
resistance protein) and MRPs (Multidrug resistance-associated protein).
Several factors have been reported to affect DMEs and transporters. These include
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genetic polymorphisms, epigenetic factors, and non-genetic factors.

Genetic

polymorphisms result in alterations in DNA sequence of genes that regulate the
expression of DMEs and transporters; and have led to loss-of-function or gain-offunction variants. The association between genetic polymorphisms and variation of
plasma concentration levels of drugs as well as response has been extensively studied
(Koren et al., 2006, Elens et al., 2011). Epigenetic influences on drug metabolism
have also been reported. These are heritable changes in gene function that are not
based on DNA sequence variation, but covalent modification of DNA, modification of
histones or microRNA regulation (Pan et al., 2009, Mohri et al., 2010). In addition to
the above, non-genetic factors like sex (Schmidt et al., 2001, Wolbold et al., 2003),
age (Cotreau et al., 2005, Stevens et al., 2008) and disease state like diabetes
(Dostalek et al., 2011 , Dostalek et al., 2012a, Dostalek et al., 2012b) affect the
expression and activity of DMEs and transporters.

1.6 Effect of NAFLD on Phase I Drug Metabolizing Enzymes
(DMEs)
1.6.1 CYP3A
This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1 and
includes four genes - 3A4, 3A5, 3A7 and 3A43 (Zanger and Schwab, 2013). It is the
most abundant human cytochrome P450 isoform in the liver and is involved in the
metabolism of about half of clinically useful drugs (Guengerich, 1999). The CYP3A5
isoform is expressed mostly in Africans (Diczfalusy et al., 2011). It also exhibits wide
inter-individual variability in its expression and activity through polymorphisms,
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epigenetic and non-genetic influences.
The influence of NAFLD on the expression and activity of CYP3A has been studied
using animal and cell culture models, human hepatic tissues, and human subjects
(Woolsey et al., 2015). Previous studies in rats and mice models are conflicting.
However, a more consistent result have been emerging showing down-regulation of
the mRNA and protein expressions, and the corresponding CYP3A activity in NAFLD
(Table 1.2 ). This is perhaps due the use of models that are able to simulate better the
metabolic and histological lesions of NAFLD. The activity of CYP3A decreased with
severity of steatosis (Kolwankar et al., 2007) and with the progression of NAFLD
(Woolsey et al., 2015). Dostalek et al. (2011) observed significantly lower protein
levels, reduced enzymatic activity of CYP3A4 and unchanged mRNA levels in
microsomal fractions of human diabetes mellitus livers (Dostalek et al., 2011). Again,
the plasma levels of atorvastatin, a substrate of CYP3A4 (Lennernäs, 2003), has been
reported to be elevated in patients with diabetes mellitus (Dostalek et al., 2012b). In
view of the high prevalence of NAFLD in the diabetic population, it is likely that
NAFLD could be involved in the down-regulation of CYP3A4 activity in the diabetic.
CYP3A genes seem to be regulated by a multiplicity of signaling pathways via
CCAAT-enhancer-binding proteins (C/EBP) (Martínez-Jiménez et al., 2005), HNF4
(Jover et al., 2009), PXR (Liu et al., 2008), and CAR (Timsit and Negishi, 2007). A
reduced CYP3A4 luciferase reporter activity in steatotic mice suggested a reduced
CYP3A4 transcription in NAFLD (Woolsey et al., 2015). The cytokine-mediated
down-regulation of CYP3A4 (Werk and Cascorbi, 2014) in the course of the
inflammatory response via the JAK/STAT (Janus kinase / Signal Transducer and
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Activator of Transcription) pathway (Jover et al., 2002 ) seem to be clinically relevant
in NAFLD and diabetic patients due to circulating cytokines. Additionally, it has been
suggested that the hepatic CYP3A4 expression is probably down-regulated by FGF21
(fibroblast growth factor 21) through the receptor-mitogen-activated protein kinase
(MAPK) pathway which leads to reduced gene transcription (Woolsey et al., 2016).

1.6.2 CYP2
The CYP2 family contains several of the most important drug metabolizing CYPs
including CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Some of
these members are highly polymorphic (Zanger and Schwab, 2013). The regulation of
the subfamilies of CYP2 appears to involve nuclear factors like PXR, CAR, GR, and
HNF4α. Conflicting results have been reported in NAFLD and diabetic models. This
is perhaps due to differences in models used. Additionally, the polymorphic nature of
some of the members of this family could be a source of discrepancy in findings
especially where the genotypes involved are not considered. Several groups have
studied the effect of NAFLD on CYP2 enzymes.

Reduced activity and mRNA

expression of CYP2A6, CYP2B6, CYP2C9 and CYP2D6 have been reported in
primary human cultured hepatocytes exposed to increasing concentrations (0.25 to 3
mM) of mixture (2:1) of oleic and palmitic acids (Donato et al., 2006). This study
suggested probable alterations in some of the CYP2 enzymes in steatosis.

1.6.3 CYP2A6
CYP2A6 is clinically relevant for the hydroxylation of coumarin.

The murine

ortholog of CYP2A6, Cyp2a5, was found to be elevated in the presence of steatosis
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(Li et al., 2013, Cui et al., 2016) similar to the observations made in human hepatic
tissues (Fisher et al., 2009). These observations however contradict the observations
made by another group (Donato et al., 2006).

1.6.4 CYP2B6
CYP2B6 is an emerging enzyme with significant importance. It is involved in the
biotransformation of several clinically relevant drugs like bupropion, efavirenz and
cyclophosphamide. It also plays a role in the inactivation of environmental toxins.
Recently, in vivo and in vitro studies using male Sprague Dawley rats and rat hepatic
tissues respectively showed down-regulation of rat Cyp2b1(rat ortholog of human
CYP2B6) activity, mRNA and protein expressions. This observation was made in
both steatotic (HF diet) and NASH (MCD-diet) models with pronounce effect in
NASH. It appears progression of NAFLD to hepatocellular carcinoma aggravates the
decrease in CYP2B6 activity (Gao et al., 2016).

Notwithstanding, Fisher and

colleagues (Fisher et al., 2009) observed a slight increase in the mRNA levels, but did
not observe any change in the protein level and activity of CYP2B6 in steatotic and
NASH human liver tissues. Since CYP2B6 is less abundant and highly variable,
evaluating the effect of heterogeneous NAFLD on its expression and activity poses a
challenge.

1.6.5 CYP2C
The CYP2C family of CYPs are responsible for the metabolism of about 12 % (Wang
and Tompkins, 2008) of clinically useful drugs. These include CYP2C8 (paclitaxel,
amodiaquine),

CYP2C9

(warfarin,

tolbutamide)
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and

CYP2C19

(phenytoin,

omeperazole). There seems to be very little information about the CYP2Cs since the
last reviews on NAFLD and DMEs (Merrell and Cherrington, 2011, Naik et al., 2013).
The available reports suggest alterations of CYP2C in NAFLD. However, the
direction of change is not clear, as both increasing and decreasing trends have been
observed (Fisher et al., 2009, Li et al., 2016). The AUC of rosiglitazone, an insulin
sensitizer and a substrate of CYP2C8 and CYP2C9 (Baldwin et al., 1999), was found
to be significantly increased in male mice after high fat and high fructose NAFLD
induction (Kulkarni et al., 2016). Nevertheless, it is not clear whether this increase
was mediated through down-regulation of the CYP2C8/9 or alteration in transport
mechanisms.

1.6.6 CYP2D6
CYP2D6 constitutes about 4 % of total CYP content, yet it is involved in the
biotransformation of more than 25 % (Wang and Tompkins, 2008) of clinically useful
drugs including dextromethorphan and bufuralol. It is highly polymorphic (IngelmanSundberg, 2005) and the few reports are conflicting. In leptin-deficient (ob/ob) mice,
the protein levels of Cyp2d22 (rat ortholog of human CYP2D6) (Li et al., 2016) were
decreased. Similarly, in human liver tissues, CYP2D6 protein levels and activity
showed a decreasing trend in NASH (Fisher et al., 2009).

1.6.7 CYP2E1
CYP2E1 is the most studied CYP enzyme in relation to NAFLD. CYP2E1 is involved
in the biotransformation of acetaminophen, ethanol, acetone and fatty acid oxidation.
It is known for the generation of ROS like hydrogen peroxide, and superoxide anion
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radicals (Aubert et al., 2011) due to uncoupling of oxygen consumption with NADPH
(Nicotinamide adenine dinucleotide phosphate) oxidation and as a by-product of lipid
peroxidation (Robertson et al., 2001). It is therefore considered to probably worsen
the oxidative stress associated with diabetes and NAFLD, and may play a key role in
the progression of NAFLD (Aubert et al., 2011). In fact, it is suspected to be a
contributor to acetaminophen-induced liver injury in obesity and NAFLD (Michaut
A1, 2014). There seem to be an increasing number of findings in the literature to
support the enhancement of expression and activity of CYP2E1 in NAFLD in both
humans and rodents (Chalasani et al., 2003, Abdelmegeed et al., 2012, Aljomah et al.,
2015). Results in rat studies have shown a consistent trend of increase in Cyp2e1
expression and activity in MCD (Methionine choline deficient) diet fed rats (Weltman
et al., 1996). Diabetes has also been reported to increase the mRNA and protein
expressions of CYP2E1 (Lucas et al., 1998, Wang et al., 2003), and perhaps
generating tissue-damaging hydroxyl radical in patients (Caro and Cederbaum, 2004).

1.7 CYP1A
The CYP1A subfamily has two functional members oriented head-to-head on
chromosome 15q24.1. These are CYP1A1 and CYP1A2 (Zanger and Schwab, 2013).
The two are highly inducible by ligands of CAR and AhR (aryl hydrocarbon receptor)
(Zanger and Schwab, 2013). CYP1A2 constitutes approximately 15 % of total hepatic
CYP enzymes (Wang and Tompkins, 2008). Its substrates include anticoagulants,
antidepressants, antihistamines and anticancer agents (Zanger and Schwab, 2013).
Reports from different groups about the down-regulation of CYP1A2 in NAFLD
appears to be one of the most consistent despite some discrepancies (Merrell and
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Cherrington, 2011). The levels of expression of mRNA and protein are decreased in
different rodent models of NAFLD (Zhang et al., 2007, Hanagama et al., 2008). In
human related tissues, down-regulation of mRNA, protein and activity have been
observed (Donato et al., 2006, Fisher et al., 2009).
Significant increases in the systemic clearance of antipyrine and protein levels of
hepatic CYP1A2 were observed in diabetic rats possibly due to the enhancement of
hepatic CYP1A2-mediated metabolism (Ueyama et al., 2007).

Similarly, the

metabolism of antipyrine was observed to be increased in patients with type 1 diabetes
(Matzke et al., 2000). The hepatic metabolism of theophylline into 1, 3- dimethyluric
acid (3-DMU) by CYP1A2 and CYP2E1 were studied using diabetes mellitus rat
models (alloxan-induced and streptozotocin-induced). A significant increase in the
AUC of 1, 3-DMU was observed in the diabetic rats compared to the controls. Based
on in vitro rat hepatic microsomal studies, the increased clearance of theophylline was
confirmed in the diabetic rats (Kim et al., 2005). Other studies in similar diabetic
models have reported similar findings (Bae et al., 2006, DY et al., 2007).

1.8 Effect on Phase II Drug Metabolizing Enzymes (DMEs)
1.8.1 UDP-glucuronosyltransferases (UGTs)
Glucuronidation is the major route for phase II reactions catalyzed by the UDPglucuronosyltransferases (UGTs). UGTs have been reported to be involved in the
glucuronidation of more than 40 % of drugs in clinical use (Wells et al., 2004). They
are anchored in the endoplasmic reticulum.

Members of the UGT1A and 2B

subfamilies appear relevant in humans due to their roles in the elimination of
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xenobiotics. In some reports, there was no change in Ugtb1 protein (rat) and UGT2B7
activity (humans) in NASH (Dzierlenga et al., 2015, Ferslew et al., 2015). An earlier
work utilizing human liver and kidney microsomes, however, observed a decrease in
the activity as well as reduction in the mRNA and protein expression of UGT2B7 in
diabetes compared to control (Dostalek et al., 2011 ). Again, it is not clear whether
the presence of NASH in the diabetic livers contributed to this observation. Limited
literature on this subject matter does not allow a clear understanding of how the
expression and activities of UGTs are modified by diabetes and NAFLD.

1.8.2 Sulfotransferases
Sulfotransferases (SULTs) are cytosolic enzymes that catalyze the sulfonation reaction
of xenobiotics and endogenous compounds by adding a sulfonate moiety to a
compound to increase its water solubility and decrease its biological activity. In
humans three SULT families, SULT1, SULT2, and SULT4 have been reported
PPARα mediates the induction of human SULTs, thus implicating a role for fatty acids
as endogenous regulators of hepatic sulfonation in humans (Runge-Morris and
Kocarek, 2005). In human patients, SULT1A2 was found to be down-regulated in
NASH (Younossi et al., 2005); and resulted in decreased plasma levels of
acetaminophen-sulfate (Canet et al., 2015). Yalcin and colleagues (Yalcin et al.,
2013) also observed that sulfotransferase activity decreased significantly with severity
of liver disease from steatosis to cirrhosis. Available reports therefore suggest that the
activities of SULT1A1 and SULT1A3 were lower in disease states compared to nonsteatotic tissues.
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1.8.3 Glutathione-S-transferases
The Glutathione-S-transferases are present as different isoforms - α (A=alpha), μ
(M=mu), π (P=pi), ϴ (T=theta), and ζ (Z=zeta) (Hayes et al., 2005).

They are

involved in the conjugation of glutathione (GSH) to reactive drug metabolites, though
this reaction can be spontaneous without GST (Dragovic et al., 2010). A number of
studies into GST activity in NAFLD and diabetes have found decreased enzymatic
activity in ob/ob mice (Barnett et al., 1992, Roe et al., 1999) and human liver samples
(Hardwick et al., 2010). GSTM2, M4 and M5 expressions were higher in African
Americans with NASH than in Caucasians (Stepanova et al., 2010).

1.9 Effect of NAFLD on efflux and uptake transporters
The down-regulation of uptake and up-regulation of efflux transporters in obese and
NAFLD have been observed in studies involving rodents and human samples (Canet
et al., 2014, Canet et al., 2015). Though interspecies variation limits the use of
rodents in modeling human NAFLD, concordance analysis has suggested that both
mouse and rat MCD models, as well as mouse ob/ob and db/db NASH models show
some similarity to human transporter mRNA and protein expression, and hence may
be useful for predicting altered drug disposition (Canet et al., 2014). Canet et al.
(2014) observed mainly up-regulation of mRNA and protein expressions of Mdr1
(multidrug resistance protein), Mrp1-4 (multidrug resistance-associated protein) and
Bcrp (Breast cancer resistance protein) in rat and mouse NASH models. Conversely,
the Oatps (organic anion transporting polypeptides) mainly showed a down-regulation
(Canet et al., 2014). The plasma concentrations of metformin, an anti-hyperglycemic
agent, were slightly increased in the WT/MCD and ob/Control groups. In ob/MCD
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mice compared to Wild Type, the plasma concentrations were 4.8-fold higher. These
changes were attributed to decreases in the kidney mRNA expression of Oct2 and
Mate1, the primary mediators of metformin elimination (Clarke et al., 2015).
In the literature, the influence of NAFLD on MRP2-3 appears more obvious compared
to other transporters (Hardwick et al., 2012, Canet et al., 2015). Table 1.3 shows
some of the published work on the effect of NAFLD on MRP3. In MCD diet-induced
NASH male Sprague-Dawley rats, mislocalization of Mrp2, the canaliculi efflux
transporter, was observed. Mrp2 appeared to pocket inward, resulting in a diminished
function of effluxing substrates into bile. On the other hand, the sinusoidal Mrp3
efflux transporter increased with respect to protein expression leading to increased
efflux of substrates into plasma (Dzierlenga et al., 2015).

These findings were

consistent with human clinical studies involving MRP3 and its morphine glucuronide
(morphine 3 and 6 glucuronides) substrate in NASH subjects (Ferslew et al., 2015).
The AUC of morphine glucuronide was 58 % higher in NASH subjects compared to
healthy subjects. The Cmax also was also significantly higher in NASH subjects. In
addition, fasting levels of total bile acids, glycocholate and taurocholate were also
elevated in NASH subjects suggesting up-regulation of the basolateral efflux MRP-3
(Ferslew et al., 2015). Clinical impact of NAFLD/NASH on pharmacotherapy
Though very few clinical studies have reported the impact of NAFLD on
pharmacotherapy, they strongly highlight the potential of NAFLD to cause variable
drug response, adverse drug reaction and eventually toxicity through alteration of
pharmacokinetic profile. Midazolam (Woolsey et al., 2015), morphine (Ferslew et al.,
2015) and acetaminophen (Canet et al., 2015) have been evaluated in both healthy and
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NAFLD patients. NAFLD seem to increase the AUC of midazolam by reducing the
activity of CYP3A4; and similarly increase the AUC of the glucuronide metabolites of
morphine and acetaminophen via the up-regulation of the MRP3 efflux transporter.
Perhaps, the available evidence in the literature is the main motivation behind the
emerging interest in drug disposition in NAFLD patients.

Hopefully, additional

clinical studies would be conducted to gain more insight into the nature and extent of
impact of NAFLD on pharmacotherapy.

1.10 Challenges to studying the effect of NAFLD on DMEs and
Transporters
Studying the effect of NAFLD on DMEs and transporters is challenging. First, the
pathogenesis of NAFLD is not clearly understood, and is usually asymptotic requiring
biopsy for definitive diagnosis. Due to ethical reasons, researchers are unable to
routinely obtain biopsies from patients for studies. Also, the presence of comorbidities particularly diabetes, which is highly prevalent in NAFLD patients, is not
accounted for. For instance, it has been demonstrated that antipyrine elimination rate
was dependent on the type of diabetes (type 1 versus type 2) and gender (Sotaniemi et
al., 2002). It was observed that insulipenia enhanced hepatic microsomal enzyme
activity (probably through increased ketone bodies), whereas relative insulin
deficiency was associated with decreased metabolic activity (Sotaniemi et al., 2002).
Since the presence of diabetes and other demographic characteristics could confound
the effect of NAFLD on DMEs and transporters, it may be necessary to account for
them. Finally, the absence of consensus on NASH models and NAFLD classification
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system to use for experiments has permitted the use of different NASH models and
classification systems.

For instance, a mice diabetic model of NASH only

recapitulated human CYP alterations in NAFLD partially (Li et al., 2016); and hence
may be inadequate for all CYPs. This has made comparison of results from some
groups difficult. It is hoped that as research advance in this earlier, these procedures
would be harmonized to allow comparability of results.

1.11 Conclusion
NAFLD and diabetes are gradually becoming pandemic globally. Limited options are
available for the treatment of NASH; hence, several pharmaceutical companies are
trying to develop new molecules for this condition. However, lack of knowledge on
the effect of NAFLD or NASH on the expression and activity of hepatic DMEs and
transporters can impede drug development in this area. Current research findings,
though limited and sometimes conflicting, suggest alterations in DMEs and
transporters in NAFLD. Few of the results however are consistent across studies and
species and includes the down-regulation of CYP3A; and up-regulation of CYP2E1
and MRP3.
conflicting.

Results from other DMEs and transporters are either lacking or
Investigating the influence of NAFLD on DMEs and transporters is

challenging because NAFLD is heterogeneous and involves a spectrum of hepatic
lesions. The challenges introduce another layer of variability to NAFLD experimental
studies. The presence of steatosis, oxidative stress and inflammatory mediators like
TNF-α and IL-6 have been implicated in the alterations of nuclear factors in NAFLD.
Consequently, the regulation of transcription factors like CAR, PXR, PPAR-α, etc.
may change and eventually alter the expression of DMEs and transporters. These
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alterations could be potential sources of drug variability in patients and could have
serious consequences on safety and efficacy. We recommend more studies in this area
to augment our understanding on the effect of NAFLD on drug metabolism.
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1.13 Tables
Table 1.1 Biomarkers and imaging techniques employed in diagnosis of NAFLD.

Diagnosis
Tools
Serological
Tests

Technique / Principle

Features

References

Aspartate
aminotransferase (AST)
Alanine
aminotransferase (ALT)
AST/ALT

Raised levels not indicative of
NAFLD because AST and
ALTs are normal in some
NAFLD patients.
> 1 is predictive of fibrosis

(Mofrad et
al., 2003,
Browning
et al., 2004,
Bugianesi
et al., 2004)

Imaging
Techniques

Ultrasonography

Sensitive when steatosis is >
30 % of hepatocytes;
Does not distinguish between
steatosis and NASH
More sensitive than
ultrasonography
Cannot distinguish between
steatosis and NASH
Expensive
Can detect fibrosis but
expensive

Computerized
Tomographic (CT)
Scanning
Magnetic Resonance
Imaging (MRI)
Transient Elastography

Liver Biopsy Histological evaluation
of hepatic tissues.
Hepatic lesions like
steatosis, inflammation
and ballooning are
graded; and fibrosis is
staged.

Gold Standard but invasive
and may be involved with
complications and sampling
variability
Able to detect steatosis and
inflammation
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(Wieckows
ka and
Feldstein,
2008)

(Ratziu et
al., 2005,
Wieckowsk
a and
Feldstein,
2008)

Table 1.2 The effect of NAFLD on CYP3A4/CYP3A5.

Overall, NAFLD progression seem to reduce the activity of CYP3A.

Study

NAFLD
Model
Human
liver
tissues
(Ex vivo)

NAFLD
category
Steatosis

mRNA

Decreased Slight
decrease

Decreased

Activity
Probe
Testosterone

(Fisher et Human
al., 2009)
liver
tissues
(Ex vivo)

Steatosis

No
change
No
change
No
change
Not
Reported

Slight
increase
Decreased

Decreased

Testosterone

Decreased

Decreased

Not
reported

Decreased
(2.4 fold)
Decreased
(2.5 fold)
Not
reported

Midazolam

Not
reported

CYP3A4
Luciferase
Reporter
plasmid

(Kolwankar
et al., 2007)

(Woolsey et Human
al., 2015)
Subjects
(in vivo)

NASH
(fatty)
NASH (not
fatty)
Steatosis

Protein

NASH

Activity

Decreased

Human
Steatosis
liver
tissues
NASH
(Ex vivo)
Female
Steatosis
Mice (In
vivo)
HFD

Decreased Not
(60 %)
reported
Decreased
(69 %)
Not
Not
reported
reported

Huh7
Steatosis
hepatoma
cells (In
vitro)

Decreased Not
(80 %)
reported

Decreased
(38 %)

Midazolam

Increase

Slight
decrease
Slight
decrease

Midazolam

Diabetic
(Li et al., ob/ob
2016)
male
Mouse
Diabetic
(In vivo) NASH
(MCD)

Increase
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Slight
decrease
Decreased

Table 1.3 The effect of NAFLD on MRP3.

Overall, NAFLD progression seem to increase the expression and activity of MRP3

Study

Species

(Hardwick et Rats
al., 2012)
SpragueDawley)

(Dzierlenga et Rats
al., 2015)
SpragueDawley)

Ref/NAF
LD
(male Control/N
ASH

(male Control/N
ASH

Endpoi
nt
mRNA
level
Protein
Plasma
Concent
ration
AUC

et Human

AUC

MRP3
Protein

Significantly
increased

Protein

Healthy/N
ASH

Cmax
AUC

(Canet et al., Human
2015)
(Children)
Human
Tissues

Healthy/S
teatosis
/NASH
Liver Healthy/S
teatosis
/NASH
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Significantly
increased
Significantly
increased
Significantly
increased
150
%
increase
Significantly
increased
Significantly
increased
52 % increase
in NASH
58 % increase
in NASH
Increased

Activity
(Ferslew
al., 2015)

Change

Probe
Substrate

Ezetimibe
glucuronide
Morphine
glucuronide

Morphine
glucuronide
Morphine
glucuronide
Acetaminophen
glucuronide

1.14 Figures

Figure 1.1 The progressive stages of NAFLD (non-alcoholic fatty liver disease)
The benign form of NAFLD, NAFL (non-alcoholic fatty liver), progresses to NASH (non-alcoholic
steatohepatitis) with or without fibrosis.

Subsequently, NASH leads to cirrhosis and eventually

hepatocellular carcinoma.
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Figure 1.2 Major components of the metabolic syndrome.
Major components of the metabolic syndrome.

The presence of at least three of these

components define the presence of metabolic syndrome.
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MANUSCRIPT II

Abstract
Aims: Tools for determination of the diabetic status of human liver tissues (HLTs)
used to study the effect of diabetes on drug metabolizing enzymes (DMEs) is lacking.
This study is aimed to establish a model-based approach for predicting the diabetic
status of donors of HLTs.
Materials and Methods: HLTs, demographic and anthropometric information were
supplied by Xenotech LLC.

Histopathological examination was conducted to

characterize non-alcoholic fatty liver disease (NAFLD) lesions.

HLTs were

homogenized and levels of feeding-related hepatic neuroendocrine peptides (amylin
(active), insulin, c-peptide, glucagon, ghrelin, GLP-1 (active), GIP, PP, PYY, leptin
and MCP-1) determined. The association between diabetes, and these covariates was
modeled using multiple logistic regression. The statistically validated model was used
to predict new diabetic classes of HLTs.
Results: A multiple logistic regression model adequately described the association
between diabetes, NAFLD lesions and the neuroendocrine peptides. Liver weight, cpeptide, leptin, PYY, Amylin (active) and steatosis were significant predictors of
diabetes. The final model had an AROC curve of 0.89, accuracy of 80%, sensitivity of
82.4% and specificity of 77%. The new diabetic classes showed that hepatic GLP-1
(active) level was 1.4 higher in non-diabetic livers compared to diabetic ones.
Conclusions: Hepatic neuroendocrine peptides and steatosis strongly predicted the
diabetic status of HLT donors.

The logistic regression model describing this
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relationship can be used as a tool to predict the diabetic status of HLTs.

Key Words:
Diabetes, liver, model, neuroendocrine, non-alcoholic fatty liver disease
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AIC: Akaike information criterion; AROC: Area under ROC curve; BAPP: Biasadjusted predicted probabilities; BMI: Body mass index; DMEs: Drug metabolizing
enzymes;
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ROC: Receiver operating

2.1 Introduction
The liver is an important organ involved in the metabolism of many drugs 1.
Consequently, many drug metabolism studies are performed using human liver tissues
(HLT) or human hepatocytes

2,3

.

Subcellular fractions, mainly microsomes and

cytosol, derived from HLTs have been used to study the metabolic pathways of new
drugs and also to investigate the influence of demography, polymorphisms and
diseases on drug metabolizing enzymes (DMEs) particularly Cytochrome P450
enzymes 4,5. Unlike primary human hepatocytes and cell lines, human liver tissues are
scarce and may not be well characterized with respect to demographic differences,
disease conditions, medication use and environmental exposures.

Despite these

limitations, certain investigations including disease effect on the expression and
activity of DMEs, are preferentially conducted in vitro using human liver tissues 6,7.
In recent times, efforts have been made to study the effect of non-alcoholic fatty liver
disease on DMEs using HLTs

6,7

. Nonalcoholic fatty liver disease (NAFLD) is a

common liver disease with global prevalence ranging from 6-35 %

8-10

. It progresses

from simple non-alcoholic fatty liver (NAFL) or steatosis to non-alcoholic
steatohepatitis (NASH), cirrhosis, and eventually hepatocellular carcinoma

11

. To

delineate the effects of NAFLD on DMEs, HLTs are characterized with respect to
steatosis and other NAFLD lesions (inflammations, ballooning, fibrosis, etc.) using
histopathological techniques. NAFLD is strongly associated with Type 2 diabetes
(T2D) via the metabolic syndrome

12,13.

Unlike NAFLD however, methods to

characterize HLTs with respect to T2D is still lacking.
Type 2 diabetes affects over 400 million people globally
67

14

, and like NAFLD, may

influence the expression and activity of DMEs. However, this influence is not clearly
understood. To study the influence of diabetes on DMEs, it is similarly important to
correctly classify the HLTs with respect to the presence or absence of diabetes. This
is important because information on the diabetic status of human livers may be lacking
or unreliable. For instance, liver donors with prediabetes or undiagnosed diabetes may
be identified as non-diabetic, although their biochemical profile may be diabetic.
Conversely, well-managed diabetic donors may be labeled as "diabetic" but may have
a more non-diabetic biochemical profile. The mismatch between diabetic labels and
the biochemical profile of donor livers can adversely affect the reliability of
investigations aimed at studying the effect of disease state on protein expression or
enzyme activity. To predict the diabetic status of HLTs, we propose a novel approach
that combines vendor-provided information and the biochemical state of the liver
tissues to confirm the diabetic status of donors.
In this study, we measured the hepatic concentrations of neuroendocrine peptides
associated with feeding and diabetes

15

. They included amylin (active), insulin, c-

peptide, glucagon, ghrelin, GLP1-active, GIP (Glucose-dependent insulinotropic
peptide), PP (pancreatic polypeptide), PYY (peptide YY), leptin, and MCP-1
(monocyte chemoattractant protein 1).

These peptides are essential to glucose

homeostasis and some others such as GLP1 and ghrelin, etc. have been targeted for the
treatment of diabetes

16,17

. Together with anthropometric information and NAFLD

lesions, a multiple logistic regression model was developed and used to predict new
diabetic status of the HLT. It is hoped that findings in this study would help in future
prediction of HLTs with unknown diabetic status; and pave the way for further
68

investigations to advance approaches to characterizing the true diabetic status of HLTs
used for drug metabolism studies.

2.2 Materials and Methods
2.2.1 Human Liver Tissues Characterization.
Diabetic (n = 51) and non-diabetic (n = 52) human livers were obtained from
XenoTech LLC (Lenexa, KS, USA) and were carefully selected based on their
similarity in demographic data. The NAFLD lesions were determined at the Liver
Research Center of Brown University Medical School according to a previously
described scoring system

18

.

This scoring system comprises a semi-quantitative

grading of steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2),
and fibrosis stage (0-4). These grades generated a NAFLD Activity Score (NAS)
ranging from 0 to 8 excluding the score from fibrosis that is less reversible. Using
established algorithms for NAFLD classification (Kleiner et al., 2005, Kleiner and
Makhlouf, 2016) the livers were grouped into NoNAFLD (n=29), NAFL (n=34) and
NASH (n=27).

2.2.2 Biochemical Analysis.
The concentration of amylin (active), insulin, c-peptide, glucagon, ghrelin, GLP1active, GIP, PP, PYY, leptin and MCP-1 in liver homogenate were determined using
the Milliplex MAP Kit, HMHEMAG-34K, (EMD Millipore Corporation, Billerica,
MA) according to manufacturer's instructions with slight modification to the sample
preparation. Briefly, liver homogenate was prepared from 200 mg human liver in
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phosphate buffer containing recommended protease inhibitors at pH=7.4 using Omni
Bead Ruptor 24 (NW Kennesaw, GA, US). The homogenate was first centrifuged to
remove debris and the concentration determined on a MagPix (Luminex, Chicago).
The concentration of the peptides were expressed in nanogram per gram of liver tissue
(ng.g-1).

2.2.3 Statistical methods
Statistical analyses. Descriptive statistics was used to summarize the demographic and
anthropometric information, NAFLD lesions and neuroendocrine data. Correlation
between hepatic neuroendocrine peptides was also obtained. Graphs were generated
using GraphPad Prism version 7.0 (GraphPad Software Inc., La Jolla, CA).

All

statistical analyses and modeling were done in SAS version 9.3 (SAS Institute, Cary,
NC).

Differences between groups were evaluated using Mann-Whitney U and

Kruskal-Wallis tests (PROC NPAR1WAY) for groups with two and greater than two
categories respectively. Both tests are nonparametric and were used because they do
not require the normality distribution assumption of data required by parametric
approaches like T-test and ANOVA (analysis of variance). Statistical differences
were considered significant at the P < 0.05 level.
Dependent variable. The vendor-provided information about the diabetic status of the
HLTs were used. Hence, livers were identified as either diabetic or non-diabetic with
no additional information about the type of diabetes. The diabetic status (Y) of the
livers was thus a dichotomous variable as shown below:

70

=

1:
0:

The dependent variable was modeled as the logit of (Y), i.e., the logit of a diabetic
liver. This is summarized below:

logit

=

1−

Independent variables. Demographic (age, ethnicity) and anthropometric information
(body weight, body mass index (BMI), liver weight) from Xenotech LLC, the NAFLD
lesions and concentration levels of the neuroendocrine peptides were used as
covariates to examine their effect on the probability of the liver donated by a diabetic
individual. Categorical variables were included as dummy variables (0 or 1), whereas
continuous variables were modeled without transformation. The continuous variables
included the hepatic levels of all the neuroendocrine peptides, age, body weight, BMI
and liver weight.

The remaining variables - ethnicity, NAFLD lesions were all

considered as categorical.

2.2.4 Modeling.
A multiple logistic model was implemented using PROC LOGISTIC to establish the
association between the logit of a diabetic liver and the covariates. The model was of
the form:

logit

= +

1 1 + ⋯+
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Where "a" is the intercept; 'b1" and "bn" are coefficients associated with the 1st and
nth covariate "X1" and "Xn". A logistic model was used because the dependent
variable was dichotomous. Model results are presented as odds ratios (OR) with 95%
confidence intervals.
Model selection and validation. Parsimonious logistic regression models were
selected using forward, backward and stepwise procedures in SAS. The adequacy of
the logistic model was examined using multiple criteria: residuals from the diagnostics
statistics, the model fit statistics (Akaike Information Criterion (AIC)), and the
Hosmer-Lemeshow goodness-of-fit test. This approach was intended to minimize the
criterion-bias associated with each technique on the model selection.
The model was validated by classification using bias-adjusted predicted probabilities
(BAPP) implemented using the CTABLE option of the PROC LOGISTIC model
statement 19. The cut-off probability for deciding whether an HLT donor is diabetic or
not was established using a decision probability. Decision rule probabilities ranging
from 0.40 to 0.95 were explored. The optimal decision probability was chosen based
on accuracy, sensitivity and specificity of the classification.

This approach

approximates the unbiased method where a training dataset is modeled and the
resulting model is used to classify a validation set

19

. The area under the receiver

operating characteristic (AROC) curve, accuracy, sensitivity, and specificity of the
final models were computed.
Prediction of the new diabetic status of the HLTs. Using the final validated logistic
model, and the optimal decision rule from the BAPP validation, new diabetic classes
72

of the human livers were predicted.
Biological validation of model. The model-based diabetic classes of the HLTs were
applied to investigate the differences between the concentration levels of GLP1 whose
plasma concentration levels between diabetic and non-diabetic populations have been
studied. Secondly, the hepatic levels of leptin, PYY, amylin (active) and C-peptide
between the diabetic and non-diabetic groups were compared with corresponding
plasma levels reported in literature.

2.3 Results
2.3.1 Demographic, anthropometric and HLT characteristics.
A total of 103 human liver tissues (Diabetic = 51, non-diabetic = 52) were used in this
work.

The covariates included demographic information, NAFLD lesions

characterization, and concentration of neuroendocrine peptides. The covariates were
grouped into categorical (Table 2.1) and continuous variables (Table 2.2 and Table
2.4) for easy statistical description. The median age of donors were similar; however,
the median BMI and liver weight were significantly higher for the diabetic donors
compared to the non-diabetic (p<0.06). The median of all the neuroendocrine peptides
were significantly higher in the non-diabetic group compared to the diabetic, except
insulin, c-peptide and leptin. Leptin level was significantly higher in the diabetic
group. The levels of insulin and c-peptide were however not different between the
two groups.
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2.3.2 Correlation among neuroendocrine peptides.
With the exception of insulin, MCP-1 and leptin, the hepatic neuroendocrine peptides
investigated in this work correlated with each other significantly Table 2.5. PYY
showed very strong correlation (correlation coefficient > 0.75, p-value <0.001) with
ghrelin, GLP-1 (active), and GIP.

2.3.3 Predictors of HLT diabetic status.
The univariate analyses showed that weight, BMI and liver weight were predictive of
the diabetic status of the HLTs (AROC curve = 0.60 and 0.64 respectively). PYY and
leptin were the most predictive neuroendocrine peptides (AROC curve = 0.73 and 0.69
respectively). The remaining neuroendocrine peptides were also predictive of diabetic
status of the HLT, except c-peptide, and insulin. None of the NAFLD lesions was
statistically significant predictor of diabetes, though NAS gave a high AROC curve of
0.56. The bivariate analyses however showed that in the presence of PYY and cpeptide, steatosis and NAS were significant predictors.

Similarly, steatosis was

predictive in the presence of amylin (active), suggesting a dependence of NAS and
steatosis on levels of PYY and amylin (active).

2.3.4 Multiple logistic regression model.
Two final multiple logistic regression models: model 1 and model 2 (Table 2.3) were
selected. In both models, liver weight, c-peptide and leptin had positive effect on the
diabetic status of the HLTs. PYY and amylin (active) on the other hand, had a
negative influence, suggesting reduced risk of diabetes with raised hepatic levels.
NAS and steatosis positively influenced the diabetic status of livers according to
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models 1 and 2 respectively.

The AROC curve of model 1 was 0.87, Hosmer-

Lemeshow p-value, 0.80; AIC 106.60; and provided optimal classification at a
decision probability of 0.55 (accuracy=75%, sensitivity=72.5%, and specificity=77%),
Figure 2.1.

Model 2 on the other hand, had AROC curve of 0.89, a Hosmer-

Lemeshow p-value of 0.16; AIC 102.60; and a decision probability of 0.5 provided
optimal classification (accuracy = 80 %, sensitivity = 82.4 % and specificity = 77 % )
of the liver tissues, Figure 2.1. On the basis of a better AIC, AROC curve and
classification indices (accuracy, sensitivity and specificity), model 2 was selected as
the best model that adequately demonstrated the relationship between the logit of
diabetes and the liver weight, c-peptide, leptin, PYY, amylin (active) and steatosis.
The graphical representation of ROC (receiver operating characteristic) curve of
models 1 and 2 have been presented in Figure 2.1. The cross tabulation of vendorsupplied and predicted diabetic labels presented in Table 2.6, summarizes the number
of livers correctly and incorrectly classified.

2.3.5 Biological validation of model.
GLP-1 is an incretin involved in postprandial insulin regulation 20. The plasma levels
in diabetic and non-diabetic subjects 21,22 have been reported; and hence was used as a
marker to test the validity of the predicted classes. We observed a 1.4 fold (nondiabetic/diabetic: 0.58 ± 0.19 / 0.41 ± 0.20 ng/g of liver) decrease in the hepatic levels
of GLP1 in diabetic compared to non-diabetic HLTs. This reduction was similar to
the 1.4 fold (control/T2D: Fasting levels = 2.87 ± 0.67 / 2.06 ± 0.43; Postprandial
levels = 3.42 ± 0.85 / 2.49 ± 0.60 pg/mL) 21 and 1.6 fold (control/T2D: Fasting levels
= 0.32 (0.18 - 0.53) / 0.20 (0.13-0.43) pM) 22 decrease in plasma GLP1 levels in T2D
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diabetic human subjects.
In the diabetic HLTs, leptin level was higher, whereas amylin (active), PYY, and cpeptide were lower when compared to the non-diabetic HLTs. Leptin plasma levels
were elevated in Type 2 diabetes 23, and amylin (active) plasma was lower

24,25

. Pre-

prandial plasma level of PYY was reported to be higher in diabetic subjects, however
after eating, it did not rise significantly compared to the non-diabetic group where
there was a 63.6 % increase in plasma PYY

26

. Another group also showed reduced

postprandial plasma PYY level in subjects with a strong history of Type 2 diabetes.
These results suggested a defect in the functioning of PYY in diabetic subjects and
corroborated with the hepatic levels shown in Figure 2.2. Plasma c-peptide has been
used as a measure of the current functioning of pancreatic β-cells, and also to
distinguish between Type 1 from Type 2 diabetes 27. The level we observed suggested
a better functioning of pancreatic β-cells in the non-diabetic group compared to
diabetic, however excessive increase may increase the risk of diabetes in accordance
with the logistic model. In addition, we detected c-peptide in all the livers suggesting
that donors may not be Type I diabetic subjects. Though the plasma levels of these
peptides may fluctuate with fasting and food intake, the established effects on diabetes
and glucose homeostasis

28,29

seem to be adequately described by the logistic

regression model described in this work.

2.4 Discussions
Human liver tissues are important in vitro tools for drug metabolism studies
particularly to investigate the influence of diseases like diabetes and NAFLD on drug
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metabolizing enzymes.

The correct detection of the influence of each of these

pathologies on DMEs depends on the accurate characterization of each HLT with
respect to the disease. Currently the techniques to predict or confirm the diabetic
status of HLT is limited. To our knowledge, this is the first study to investigate the
hepatic levels of feeding-related neuroendocrine peptides, and to model the
relationship between diabetes, liver weight, steatosis and the neuroendocrine peptides.
In this study, we used vendor-provided information, hepatic neuroendocrine levels and
NAFLD lesions to establish a logistic regression model for prediction of the diabetic
classes of HLTs. This study confirmed that neuroendocrine peptides: PYY, leptin,
amylin (active) and c-peptides are significant predictors of diabetes. Though steatosis,
an important component of the NAFLD spectrum, and NAS were not significant
predictors of the diabetic status of HLTs independently, they became significant in the
presence of PYY and amylin (active), corroborating current knowledge about the
intricate association of diabetes and NAFLD through the metabolic syndrome

10

.

Additionally, our findings showed that liver weight was also a significant predictor
with or without the presence of neuroendocrine peptides. This is not surprising since
the liver weight is proportional to body weight

30

which is a predictor of diabetes.

Overall, this study presented a multiple logistic regression model that was capable of
predicting new diabetic classes of HLTs.
The most common markers used in clinics for diagnosis and monitoring of diabetes
include fasting blood glucose (FBG), oral glucose tolerance test (OGTT), hemoglobin
A1c (HbA1c) and c-peptide

31-33

. The FBG, OGTT and HbA1c tests give indication

about the plasma glucose concentration, where chronically elevated levels suggest
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impaired glucose tolerance (IGT) resulting from defective insulin secretion or
function. Plasma c-peptide levels directly measures the functionality of the pancreatic
β-cells, which secrete insulin and hence have been used to aid the differentiation
between Type 1 and Type 2 diabetes. C-peptide thus serves as a good surrogate for
insulin secretion since insulin undergoes significant first pass metabolism

34

, and in

patients receiving exogenously administered insulin, levels may not be accurate as
both exogenous and endogenous insulin are detected together by assays

27

.

Our

findings, at the hepatic level was in line with the use of c-peptide as a marker for
diabetes.
Furthermore, recent drug development efforts for T2D therapies have targeted the
incretin system

35,36

leptin and PYY

38

and other feeding-related neuroendocrine peptides like amylin 37,

. This is based on their effect on glucose homeostasis and hence

association with diabetes.
exenatide

17

, liraglutide

16

More importantly is the GLP-1 receptor agonists like
and semaglutide

39,40

, which have been successfully

developed for the treatment of T2D. The evidence available in literature thus support
that our model is pharmacologically plausible.
The choice of model 2 over model 1 was done on the basis of the improved accuracy,
sensitivity and specificity when NALFD was incorporated as steatosis instead of NAS.
Notwithstanding, both emphasize the strong association between diabetes, NAFLD
and feeding-related neuropeptides at the hepatic level. To prevent autocorrelation in
the models, PYY which was a superior predictor was selected instead of GLP-(active),
Ghrelin and GIP which correlated strongly. Our model will thus be particularly useful
for predicting the diabetic classes of HLT, particularly T2D (since we detected c78

peptide in all the liver tissues), for studying effect of diabetes on DMEs. This model
is not meant to be used for clinical diagnosis but for in vitro experiments.
Some of the limitations of this work include the lack of information about the presence
of prediabetes and the type of diabetes of the liver donors. Secondly, we were unable
to ascertain whether the livers were donated preprandially or postprandially. Finally,
we did not have the full record of the medications taken by the donors.
Notwithstanding, our model was adequate to recapitulate the known relationship
between diabetes, feeding-related neuroendocrine peptides, NAFLD and liver weight.
In conclusion, we have presented a pharmacologically plausible model that shows the
intricate relationship between diabetes, steatosis and feeding-related peptides. We
have also demonstrated the ability of this model to predict the diabetic status of human
liver tissues. It is hoped that findings in this study would pave the way for further
investigations to develop more approaches to characterizing the diabetic status of
human liver tissues used for drug metabolism studies.
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2.6 Tables
Table 2.1 Description of Human Liver Tissue (HLT) donors.

Categorical variables from demographic data (Gender and Ethnicity) and nonalcoholic fatty liver disease characterization (NAFLD).
Variable
Diabetic status
Gender

Ethnicity

Steatosis ( % of
hepatocytes fatty)

Lobular_inf (Overall
assessment of all
inflammatory foci)

Hepatocyte_Ballooning

Fibrosis

NAFLD Activity Score
(NAS)

Definition
Diabetic (D)
Non-diabetic (ND)
Female
Male
Caucasian (0)
African American (1)
Hispanics (2)
<5
5 – 33
> 33 - 66
> 66
No foci
2 foci per 200X field
2-4 foci per 200X field
> 4 foci per 200X field
Non
Few balloon cells
Prominent ballooning
None
Perisinusoidal or
periportal
Perisinusoidal and
portal/periportal
Bridging fibrosis

The unweighted sum of
steatosis, lobular
inﬂammation, and
hepatocellular
ballooning scores
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0
1
0
1
0
1
2
0
1
2
3
0
1
2
3
0
1
2
0
1

Frequency
(D/ND)
52
51
49 (25/24)
54 (26/28)
88 (43/45)
10 (5/5)
5 (3/2)
39 (19/20)
24 (15/9)
20 (8/12)
20 (9/11)
26 (11/15)
60 (31/29)
15 (9/6)
2 (0/2)
64 (28/36)
30 (18/12)
9 (5/4)
42 (19/23)
45 (24/21)

2

10 (6/4)

3
0
1
2
3
4
5
6
7

6 (2/4)
14 (4/10)
24 (14/10)
16 (10/6)
15 (6/9)
17 (9/8)
9 (5/4)
4 (1/3)
4 (2/2)

Category

Table 2.2 Description of characteristics of Human Liver Tissues (Continuous variables).

Continuous variables from demographic (Age), anthropometric data (Weight, BMI,
Liver weight) and hepatic concentration of neuroendocrine peptides (ng/g of liver).
Data summarized according to diabetes category.
Variable
Age (years)
Weight (kg)
BMI (kg/m2)

Diabetic Status
D
ND
D
ND
D

ND
D
Liver Weight (g)
ND
D
C-Peptide
ND
D
Ghrelin
ND
D
GIP
ND
D
GLP1 (Active)
ND
D
Glucagon
ND
D
Insulin
ND
D
Leptin
ND
D
MCP2
ND
D
PP
ND
D
PYY
ND
D
Amylin_Active
ND
ND: Non-diabetic; D: Diabetic.

N
51
52
51
52
51

Median (min-max)
51 (21-78)
53.5 (21-76)
94 (51-213)
85 (48-159)
34 (18-89)

52
51
52
51
52
51
52
51
52
51
52
51
52
51
52
51
52
51
52
51
52
51
52
51
52

28.5 (17-54)
1719 (1016-4375)
1522 (884-3181)
1.3 (0.5-2.7)
1.6 (0.5-2.9)
0.19 (0.09-0.39)
0.27 (0.1-0.62)
0.15 (0.03-0.32)
0.19 (0.06-0.34)
0.4 (0.15-0.91)
0.54 (0.09-1.02)
0.75 (0.36-2.1)
1.1 (0.28-2.75)
5.56 (1.33-24.68)
5.5 (1.02-23.16)
95.38 (28.04-276.98)
68.68 (15.46-183.5)
1.67 (0.33-13.18)
1.72 (0.42-22.38)
0.22 (0.05-0.51)
0.27 (0.1-0.66)
1.46 (0.76-2.17)
1.87 (1.04-2.83)
0.89 (0.27-1.66)
1.14 (0.51-2.8)

*P-values were obtained using nonparametric Mann-Whitney U test.
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p-value
0.7
0.06
0.008
0.04
0.09
0.0003
0.004
0.002
0.005
0.9
0.0007
0.8
0.008
0.0001
0.007

Table 2.3 Multiple logistic regression model predicting the diabetic status of human
liver tissues.

Model 1 (NAFLD was incorporated as NAFLD activity score (ref=0, when NAS
<2));
and Model 2 (NAFLD was incorporated as steatosis, (ref=0, when steatosis <33 %)).
MODEL1
Parameter

Intercept
Liver Weight
PYY
C-Peptide
Leptin
Amylin
(active)
NAS (ref=0)
MODEL 2
Parameter
Intercept
Liver Weight
PYY
C-Peptide
Leptin
Amylin
(active)
Steatosis
(ref=0)

Beta
Coefficient

Standard
Error

p-value

Odds
Ratio

95 %
Confidence
Limit

0.5481
0.00122
-4.2113
2.8297
0.0166
-2.2311

1.7122
0.0006
1.124
0.9721
0.00607
0.8877

0.7489
0.0285
0.0002
0.0036
0.0061
0.012

1.001
0.015
16.941
1.017
0.107

1.000 - 1.002
0.002 - 0.134
2.52 - 113.872
1.005 - 1.029
0.019 - 0.612

1.8378

0.6558

0.0051

6.283

1.737 - 22.718

Beta
coefficient
0.85
0.00137
-4.7323
2.7635
0.0152
-2.2536

Standard
error
1.7982
0.0006
1.2311
0.9953
0.0059
0.8892

p-value

Odds
Ratio

95 % CI

0.6364
0.0206
0.0001
0.0055
0.0099
0.0113

1.001
0.009
15.855
1.015
0.105

1.000 -1.003
0.001 - 0.098
2.254 - 111.53
1.004 - 1.027
0.018 - 0.600

2.3874

0.7327

0.0011

10.885

2.589 - 45.766
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2.7 Figures

Figure 2.1 Classification indices of logistic regression models.

Graphical representation of classification indices of logistic regression models used
for predicting diabetic classes of human liver tissues. Upper graphs: ROC curves for
Models 1 and 2; Lower graphs : accuracy, sensitivity and specificity graphs for
Models 1 and 2. On the basis of accuracy, sensitivity and specificity a decision
probability of 0.55 was selected for Model 1, and 0.5 for model 2. The chosen
decision probabilities are shown by arrows on respective graphs. In model 1, NAFLD
was incorporated as NAS whereas in Model 2 it was added as steatosis.
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Figure 2.2 Comparison of hepatic levels of feeding related-neuroendocrine peptides.

Feeding related-neuroendocrine peptides used for biological validation of the
model (GLP1 (active), leptin, amylin (active), c-peptide and PYY). The hepatic
levels were statistically significant (p < 0.01) between the non-diabetic (n=42) and
the diabetic group (n=40)
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2.8 Supplementary Information
Table 2.4 Description of characteristics of HLTs (Continuous variables).

Continuous variables from demographic (Age), anthropometric data (Weight, BMI,
Liver weight) and hepatic concentration of neuroendocrine peptides (ng/g of liver).
Data summarized according to nonalcoholic fatty liver disease (NAFLD) grouping.

Variable

Age

Weight (kg)

BMI (kg/m2)

Liver Weight (g)

C-Peptide

Ghrelin

GIP

GLP (active)

Glucagon

Insulin

Leptin

Category

N

Median (min - max)

NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL

39
35
29
39
35
29
39
35
29
39
35
29
39
35
29
39
35
29
39
35
29
39
35
29
39
35
29
39
35
29
39
35

49 (21 - 78)
54 (33 - 76)
51 (33 - 74)
78 (55 - 213)
93 (48 - 191)
91 (69 - 158)
28 (18 - 89)
31 (17 - 70)
32 (22 - 52)
1465 (884 - 2300)
1902 (1053 - 4375)
1819 (1180 - 3685)
1.7 (0.9 - 2.9)
1.2 (0.5 - 1.9)
1.1 (0.8 - 2)
0.31 (0.17 - 0.51)
0.19 (0.09 - 0.58)
0.19 (0.09 - 0.62)
0.21 (0.09 - 0.34)
0.15 (0.03 - 0.29)
0.15 (0.06 - 0.27)
0.55 (0.27 - 1.02)
0.39 (0.15 - 0.93)
0.37 (0.09 - 0.81)
1.09 (0.4 - 2.17)
0.74 (0.36 - 2.75)
0.83 (0.28 - 1.76)
6.23 (1.96 - 23.16)
5.56 (1.33 - 24.68)
4.77 (1.02 - 22.99)
74.24 (15.46 - 191.78)
81.01 (30.24 - 276.98)

91

P-value
0.2

0.1

0.2

0.006

0.0001

0.0001

0.001

0.0001

0.03

0.2
0.3

MCP1

PP

PYY

Amylin (Active)

NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH
NoNAFLD
NAFL
NASH

29
39
35
29
39
35
29
39
35
29
39
35
29

96.62 (24.65 - 222.36)
1.66 (0.33 - 9.09)
1.63 (0.51 - 13.18)
2.42 (0.42 - 22.38)
0.32 (0.18 - 0.66)
0.22 (0.1 - 0.42)
0.2 (0.05 - 0.41)
1.95 (1.35 - 2.68)
1.45 (0.76 - 2.83)
1.47 (0.92 - 2.47)
1.19 (0.47 - 2.8)
0.87 (0.27 - 1.89)
0.9 (0.55 - 1.52)

*P-values were obtained using nonparametric Kruskal-Wallis test.
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0.6

0.0001

0.0001

0.008

Table 2.5 Correlation between the hepatic neuroendocrine peptides.

Correlation between the hepatic neuroendocrine peptide concentrations (ng/g of liver).
CPeptide
C-Peptide
Ghrelin
GIP
GLP-1
(Active)
Glucagon
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Insulin
Leptin
MCP-1
PP
PYY
Amylin
(active)

Ghrelin

GIP

GLP-1
(Active)

Glucagon

Insulin

Leptin

MCP1

PP

PYY

Amylin
(active)

1.00
0.71
<.0001
0.67
<.0001
0.71
<.0001
0.33
0.0007
0.09
0.4
-0.17
0.09
0.02
0.9
0.68
<.0001
0.68
<.0001
0.61
<.0001

1.00
0.74
<.0001
0.74
<.0001
0.60
<.0001
0.11
0.3
-0.28
0.004
-0.04
0.7
0.62
<.0001
0.83
<.0001
0.51
<.0001

1.00
0.63
<.0001
0.52
<.0001
0.04
0.7
-0.25
0.01
-0.01
0.9
0.74
<.0001
0.79
<.0001
0.52
<.0001

1.00
0.48
<.0001
0.20
0.0
-0.25
0.010
0.08
0.4
0.62
<.0001
0.75
<.0001
0.45
<.0001

1.00
0.05

1.00
0.6

-0.14

-0.06
0.1

-0.12

1.00
0.6

0.03
0.2

0.7

0.42
<.0001
0.59
<.0001
0.26
0.007

0.02
0.8533
0.10
0.3
-0.08
0.4

-0.12
0.2
-0.23
0.0188
-0.26
0.01
-0.12
0.2

1.00
-0.01
0.9002
-0.12
0.2
0.08
0.4

1.00
0.72
<.0001
0.46
<.0001

1.00
0.52
<.0001

1.00

Correlation coefficient are aligned to the left (shaded rows); and p-values associated with correlation coefficients aligned to
the right (unshaded rows).

Table 2.6 Cross tabulation.

Cross tabulation of vendor-provided diabetic labels and predicted diabetic classes.

Vendor-provided
Diabetic label
ND
D
Total

Predicted Diabetic
Class
ND
D
Total
40
12
52
9
42
51
49
54
103

ND: Non-diabetic; D: Diabetic; Shaded cells are correctly predicted livers.
40 out of 52 livers were predicted correctly as non-diabetic. 42 out of 51 liver tissues
were predicted correctly as diabetic.
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MANUSCRIPT III

Abstract
Despite the initial belief that Cytochrome P450 (CYP) 2B6 is of minor significance, it
is now recognized as a clinically relevant drug metabolizing enzyme. The impact of
non-alcoholic fatty liver disease (NAFLD) on drug metabolism has been identified;
however, it is still unclear how it influences CYP2B6. We used in vitro approaches in
human liver microsomes (HLM) and HepaRG cells to investigate the effect of
NAFLD on CYP2B6-mediated formation of hydroxybupropion. The presence of
NAFLD increased the km significantly (p < 0.04) and reduced CYP2B6 intrinsic
clearance 2-fold.

The results from the HepaRG cells qualitatively recapitulated

findings in the HLMs. Fatty acid accumulation in hepatocytes seems to be involved
with the alteration. This investigation is hoped to contribute to our current knowledge
on the influence of NAFLD on CYP2B6 in vitro kinetics and offers the opportunity
for further studies in a clinical trial.

Keywords
Bupropion, Hydroxybupropion, Cytochrome P450 2B6, fatty acids, NAFLD, NASH,
Steatosis,
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Abbreviations:
AUC - Area Under (the plasma concentration) Curve
BSA - Bovine Serum Albumin
CAR/NR1I3 - Constitutive Androstane Receptor; nuclear factor subfamily 1, group I,
member 3
CLint - Intrinsic Clearance
CYP - Cytochrome P450
FAF - Fatty Acid Free
EMEM -Eagle's Minimum Essential Medium
HBUP - Hydroxy Bupropion
HF - High-fat
HLT - Human Liver Tissue
HLM - Human Liver Microsome
km - Michaelis-Menten constant
MCD - Methionine-Choline Deficient
MPPGL - Microsomal Protein Per Gram of Liver
NAFLD - Non-Alcoholic Fatty Liver Disease
NAS - NAFLD activity score
NASH - Non-Alcoholic Steatohepatitis
PBPK - Physiologically-based Pharmacokinetics
PBS – Phosphate Buffer Saline
PXR/NR1I2 - Pregnane X receptor; Nuclear factor subfamily 1, group I, member 2
ROC - Receiver Operating Characteristic
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UPLC/ MS/MS - Ultra Performance Liquid Chromatography tandem Mass
Spectrometry
Vmax - Maximum Velocity
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3.1 Introduction
Cytochrome P450 (CYP) 2B6 is one of the drug metabolizing enzymes (DMEs)
mainly expressed in the liver (Mimura et al., 1993). Though it is considered a minor
DME, it is involved in the biotransformation of clinically relevant drugs like
bupropion (Hesse et al., 2000), efavirenz (Ward et al., 2003), and cyclophosphamide
(Xie et al., 2003). Bupropion and efavirenz are also used as sensitive probe substrates
for phenotyping CYP2B6 activity via the formation of hydroxybupropion (Hesse et
al., 2000) and 8-hydroxyefavirenz (Ward et al., 2003) respectively.
The expression and activity of CYP2B6 is highly variable among individuals. The
sources of variability include polymorphisms in the CYP2B6 gene, induction via the
constitutive androstane receptor (CAR, NR1I3) and pregnane X receptor (PXR,
RN1I2) (Faucette et al., 2006), inhibition by potent agents like ticlopidine (Turpeinen
et al., 2005), and disease state. The study of hepatic diseases as a source of variability
in DMEs is crucial because, hepatic clearance constitutes about 60% of major
clearance mechanisms of clinically relevant drugs (Williams et al., 2004).
The effect of alcoholic liver disease (ALD) on the disposition of a single dose (200
mg) bupropion was studied in human subjects (healthy (n=8) and ALD (n=8))
(DeVane et al., 1990). Compared to healthy subjects, the ALD subjects had elevated
AUC of bupropion (~57 %) and hydroxybupropion (~53 %). The changes in the other
metabolites of bupropion, erythrohydrobupropion (EB) and threohydrobupropion
(TB), were however minimal. The apparent clearance of bupropion reduced from 187
to 145 L/hr in ALD subjects. There was also a large intersubject variability in the
pharmacokinetics of bupropion, especially in the ALD subjects, where bupropion half99

life ranged from 2.2 - 29.9 hours. Though the study was conducted in a limited
number of subjects, the findings highlighted the potential influence of hepatic diseases
on the disposition of bupropion, hence on CYP2B6 that is responsible for the
formation of hydroxybupropion.
Similar to ALD is nonalcoholic fatty liver disease (NAFLD) (Toshikuni et al., 2014).
NAFLD is emerging as one of the commonest liver diseases worldwide. Its global
prevalence is estimated to range from 6-35 % (Bellentani, 2017, Cobbina and
Akhlaghi, 2017). NAFLD progresses from steatosis, also known as nonalcoholic fatty
liver (NAFL), to fibrosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and
eventually hepatocellular carcinoma (HCC) (Angulo, 2002).

These lesions cause

alterations in inflammatory and biochemical pathways which subsequently interfere
with normal hepatic regulation of drug metabolism and glucose homeostasis (Cobbina
and Akhlaghi, 2017). NAFLD is strongly associated with the metabolic syndrome and
is common in obesity (Bellentani et al., 2010), Type 2 diabetes (Anstee et al., 2013)
and HIV/AIDs patients (Verna, 2017). In view of the high prevalence of NAFLD in
the population, several groups have evaluated the impact of NAFLD on drug
metabolizing enzymes (Fisher et al., 2009, Woolsey et al., 2015, Canet et al., 2015,
Ferslew et al., 2015).
Though a number of the studies that examined the impact of NAFLD on DMEs did
not observe alterations in the expression and activity of CYP2B6, others have
highlighted the potential impact of NAFLD on CYP2B6 where the presence of NASH
reduced gene expression (Yoneda et al., 2008, Stepanova et al., 2010). In high-fat
induced steatotic male C57/BL6 mice, the expression of Cyp2b10, (the mouse
100

ortholog of the human CYP2B6), was reduced (Kirpich et al., 2011). Similarly, in
human liver tissues the gene expression of CYP2B6 was reduced in the Non-NASH
group (Stepanova et al., 2010, Yoneda et al., 2008).

A more recent study in

Sprague−Dawley rats fed with a methionine/choline deficient (MCD) diet to induce
NASH, showed marked reduction in activity, mRNA and protein expression of
Cyp2b1 (rat ortholog of human CYP2B6) (Cho et al., 2016). Additionally, the in vitro
kinetic parameters determined using the rat liver microsomes showed 26 % reduction
in Vmax and 2.4 fold reduction in Km of Cyp2b1. Consequently, the bupropion AUC
in the rat NASH model was about 1.9-fold higher compared to control. Conversely,
the same study reported no change in the activity, mRNA and protein expression of
Cyp2b1 in high-fat diet induced steatotic rats (Cho et al., 2016). Another key group
observed increasing trend (p=0.003) in the relative mRNA expression of CYP2B6 in
NAFLD human liver tissues compared to control.

Relative protein expression,

however, showed a decreasing trend from steatosis to NASH (no longer fatty) (Fisher
et al., 2009). The current evidence in the literature do not agree very well. This lack
of consensus may emanate from the variableness of the expression and activity of
CYP2B6; and disparity in the different models used for the investigations (Li et al.,
2018).
Despite the important contributions by other groups to this field, the activity together
with in vitro kinetics of CYP2B6 in human liver tissues have not been evaluated with
respect to NAFLD. Though, gene and protein expression information helps us gain
mechanistic insight into the expression of enzymes, for the purposes of translational
pharmacokinetics (in-vitro-in-vivo extrapolation (IVIVE)), information about the
101

activity and kinetics of an enzyme is more useful.

Hence, in this study, we

investigated the influence of NALFD on the activity and kinetics of CYP2B6 using
bupropion hydroxylation as probe. To reduce the heterogeneity in the human liver
tissues, the livers were characterized with respect to demography, genetic
polymorphisms, and diabetes. We examined further the effect of NAFLD on CYP2B6
using fatty-acid-treated HepaRG cell lines. With the aid of a physiologically-based
pharmacokinetic (PBPK) model (Rowland et al., 2011) implemented in Simcyp
simulator (Jamei et al., 2009), we simulated the potential effect of NAFLD on the
biotransformation of bupropion to hydroxybupropion. This investigation is hoped to
contribute to our current knowledge on the influence of NAFLD on CYP2B6 in vitro
kinetics and offers the opportunity for further studies in a clinical trial.

3.2 Materials and Methods
3.2.1 Chemicals and Reagents.
Bupropion hydrochloride (BUP), hydroxybupropion (HBUP), hydroxybupropion-d6,
chlorzoxazone (CZ), 6-hydroxy chlorzoxazone (6-OH CZ), and 6-hydroxy
chlorzoxazone-d2 were purchased from Toronto Research Chemicals Inc. (North
York, Canada); LC/MS-grade, acetonitrile, ammonium acetate and formic acid were
from Fisher Scientific (Fair Lawn, NJ); potassium phosphate monobasic and
potassium phosphate dibasic were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P450
reductase was obtained from EMD Millipore (Billerica, MA). All other reagents and
solvents were obtained from general commercial suppliers and used without further
purification. Solutions were prepared in accordance with manufacturers' instructions.
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3.2.2 Experiments in Human Liver Tissues
Characterization of human liver tissues (HLT). Human livers from donors with
diabetes (n=53) and without diabetes (n=53) were obtained from XenoTech LLC
(Lenexa, KS, USA). These were matched based on age, gender and degree of liver
fat. The presence of NAFLD was established by histological evaluation of the livers
in a blinded fashion.

A semi-quantitative grading of steatosis (0-3), lobular

inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis staging (0-4)
permitted the classification of the livers into NoNAFLD, NAFL and NASH according
to the SAF (steatosis, activity and fibrosis) algorithm (Bedossa et al., 2012, Kleiner
and Makhlouf, 2016, Cobbina and Akhlaghi, 2017). The diabetic status of livers were
confirmed using a logistic regression model established by our lab [manuscript in
preparation]. The model had an AROC curve of 0.89 and was accurate (80 %),
sensitive (82.4%) and specific (77%).

Predicted probability of each liver being

diabetic was determined. Using a previously established decision probability of 0.5,
liver was categorized nondiabetic if predicted probability was less than 0.5 and
diabetic if greater than 0.5. The predicted diabetic class was compared with the
original vendor-provided labels to determine the correctly classified and the
misclassified (false positives and negatives) livers. This approach was carried out to
reduce intrinsic experimental error due to misclassification of the diabetic status of
HLTs. Misclassified livers were removed from analyses when CYP2B6 activity and
expression were compared between diabetic and nondiabetic groups.
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Human liver microsome (HLM) isolation: The human liver microsomes were
prepared by differential ultracentrifugation.

Briefly, 200 mg of HLT was

homogenized in 100 mg liver tissue/ 300 uL of homogenization buffer (100 mM
potassium phosphate buffer, pH=7.4; 1 mM EDTA; 0.1 mM potassium chloride; 8.55
g of sucrose; and 0.02 mM butylated hydroxytoluene) using Omni Bead Ruptor 24
(NW Kennesaw, GA, US). Homogenate was centrifuged at 10,000g for 30 min at 4
o

C and the supernatant was collected and centrifuged at 100,000g for 60 min at 4 oC.

The supernatant, cytosolic fraction, was collected and stored at -80°C.

The

microsomal pellet was then washed with 100 mM potassium pyrophosphate buffer
(pH=7.4) and re-suspended in 1000 mg liver tissue/ 660 uL of storage buffer (100 mM
phosphate buffer, pH=7.4; 20% glycerol and 1 mM EDTA). Prepared microsomes
were stored at -80°C until analysis. Total protein concentrations were determined
using a bicinchoninic acid (BCA) assay in accordance with manufacturer's instructions
(Pierce-Fisher, Rockford, IL, USA).

Human Liver Microsomal Incubation: The activity of CYP2B6 was measured using
bupropion hydroxylation, by examining varying concentrations of bupropion (0, 10,
50, 100, 400, 800, 1600 uM) in an incubation buffer (100 mM potassium phosphate
buffer (pH=7.4), and ~3 mM magnesium chloride, and 1 mM EDTA) containing 0.05
mg.mL-1 of HLM. All incubations were carried out in accordance with previously
described methods with slight modification (Faucette et al., 2000, Walsky and Obach,
2009). The incubation mixture containing bupropion was pre-incubated for 5 mins in
a water bath at 37 oC; and reaction initiated by addition of ~1.3 mM NADPH. This
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was incubated for 10 mins and then terminated with 20 uL of ice cold 5:92:3
acetonitrile/water/formic acid containing hydroxy bupropion-d6 internal standard.
The final incubation mixture was 200 uL. After centrifugation at 3000 rpm for 10
mins at 4 oC, the supernatant was collected and the amount of hydroxybupropion
formed was quantified using liquid chromatography/ tandem mass spectrometry
methodologies (UPLC-MS/MS). The rate of hydroxybupropion formation was then
calculated and the in vitro kinetics estimated.

RNA Content determination using Reverse transcription-polymerase chain reaction
(qRT-PCR): Total RNA was isolated from the HLTs using the RNeasy Mini Kit
(Qiagen, Valencia, CA).

The total RNA was reverse-transcribed, and the single

stranded DNA was used for real-time PCR. The mRNA expression of hepatic CYP
was quantified by real-time PCR using an Applied Biosystems 7500 Real-Time PCR
system (Applied Biosystems) at least two times according to the manufacturer’s
instructions. Primer sequences for the CYP2B6, CAR, and PXR are reported in
supplementary Table 3.5. 18S ribosomal RNA (rRNA) was also quantified as an
internal control.

CYP2B6 Genotyping of HLTs: Genomic DNA was isolated from the HLTs using
QIAamp DNA Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s
instructions and genotyped for two single nucleotide polymorphisms (SNPs) in the
P450 CYP2B6: CYP2B6*5 (rs3211371; 25505C>T) and CYP2B6*6 (rs3745274;
15631G>T).

The CYP2B6 SNPs were determined by Taqman® Allelic
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Discrimination Assays and Taqman Genotyping Mastermix (Applied Biosystems,
Foster, CA) on ViiA™ 7 Real-Time PCR System (Applied Biosystems).

3.2.3 Experiments in HepaRG Cell Lines
Cell Culture: HepaRG cell lines have been used for drug metabolism studies because
of its ability to express various Cytochrome P450 enzymes including CYP2B6
(Kanebratt and Andersson, 2008). The HepaRG cells (passages 2-5) were obtained
from Biopredic International (Rennes, France), and were cultured and differentiated in
accordance with manufacturer's instructions. Steatosis was induced with 500 μM fatty
acids (1:2 palmitate : oleate) conjugated to albumin in 30% essential fatty acid free
(FAF) bovine serum albumin (BSA) solution (Invitrogen, Grand Island, NY) by
modifying a previously described method (Brown et al., 2013). The cells were treated
for 72 h and media replenished after 48 h.
Oil Red O Staining: Fatty-acid-treated and control HepaRG Cells were washed twice
with PBS and fixed in 4% paraformaldehyde (Sigma-Aldrich, Saint Louis, MO) for 30
min at room temperature. Cells were washed with PBS and subsequently incubated
with Oil Red O (Sigma-Aldrich, Saint Louis, MO) in PBS for 20 mins at room
temperature. After three washes, cells were incubated with hematoxylin (SigmaAldrich, Saint Louis, MO) for 1 min to stain the nuclei and imaged to examine
intracellular lipid accumulation using EVOS cells imaging systems (Life technologies,
Foster City, CA). Subsequently, the cells were examined spectrophotometrically in
100% isopropanol using Spectromax (Molecular Devices, Sunnyvale, CA) at 492 nm.
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RNA Extraction: For mRNA measurements, total RNA was isolated from both
control and fatty-acid-treated HepaRG cells using the RNeasy Mini kit according to
the manufacturer's instructions (Qiagen, Valencia, CA). The quantity and quality of
the RNA were determined using Nanodrop 1000 spectrophotometer (Thermo
Scientific, Wilmington, DE). The cDNA was prepared from 1 μg of total RNA using
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA) in accordance with the manufacturer’s instructions. DNAse treatment (Qiagen,
Valencia, CA) was included to avoid genomic DNA contamination.
Real-Time PCR. Quantitative real-time PCR analyses of both fatty-acid-treated and
control were performed with specific sets of Taqman primers and Taqman probes for
CYP2B6 (Hs03044634_m1), PXR (Hs01114267_m1), CAR (Hs00901571_m1), 18S
(Hs03003631_g1), GAPDH (Hs99999905_m1) and β-actin (Hs99999903_m1) using a
ViiA™ 7 Real-Time PCR system in accordance with the manufacturer's instructions.
GAPDH, 18 S and β-actin were used as endogenous controls to normalize the data.
All runs were carried out in triplicate; and data analyzed using DataAssist software
(Thermo Fisher Scientific, Waltham, MA).
Insulin-stimulated phosphorylation of AKT: Following 72 h treatment, HepaRG cells
were placed in serum free EMEM media for 12 h followed by stimulation with
recombinant human insulin (Roche Diagnostics, Indianapolis, IN) at 1, 10 or 100 nM
for 10 minutes at 37⁰C. Samples were rinsed in PBS and lysed with RIPA buffer
(150mM NaCl, 50mM Tris, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM
EDTA) supplemented with complete protease inhibitor cocktail (Roche Diagnostics)
and HALTTM phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA) for 30
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minutes at 4⁰C. The lysate was run on sandwich ELISA kit that detected both pAkt
(Ser473) and total Akt (Abcam, Cambridge, MA).

The assay was performed in

accordance with the manufacturer’s protocol.
Activity studies: Both control and fatty-acid-loaded HepaRG Cells were incubated
with varying concentrations of bupropion (100, 250, 500, 750, 1000, 2500 uM), and
chlorzoxazone (500, 750, 1000 μM) for 1 and 8 h in Williams' medium E in triplicates.
The compounds were dissolved in DMSO in such a way that the final concentration
was less than 0.1%. The reaction was terminated with equal volume of ice-cold
acetonitrile containing 0.1% formic acid and deuterated internal standards
(hydroxybupropion-d6 for bupropion and chlorzoxazone-d2 for chlorzoxazone
respectively).

The formation of hydroxybupropion and 6-hydroxy chlorzoxazone

were determined using UPLC-MS/MS.

3.2.4 UPLC-MS/MS measurements.
Hydroxybupropion and 6-hydroxy chlorzoxazone were quantified using ACQUITY
UPLC™ chromatographic system (Waters Corp., MA, USA) and an API 3200 triple
quadrupole mass spectrophotometer (Applied Biosystems, Foster City, CA) with
positive electrospray ionization.

Chromatographic separation was achieved using

Waters ACQUITY C-18 column (50 × 2.1 mm; 1.7 μm particle size) and waters
ACQUITY UPLC C-18 Vanguard pre-column. Mobile phase A (10 mM aqueous
ammonium acetate, 5% acetonitrile) and B (100% acetonitrile) were pumped at a flow
rate of 0.45 mL.min-1 using a gradient ranging from 2% B at 0 to 0.5 mins, 32% B at
2.4 to 2.7 mins, 2% B at 2.9 to 4.5 mins. The column temperature was maintained at
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32 oC.
For hydroxybupropion, optimal conditions for the MRM scan in the positive
ionization mode were: ion spray voltage, 5500 V; curtain gas, 35 L/h; ion source Gas1,
55 L.h-1; ion source Gas2, 50 L.h-1; temperature, 450 oC; collision Gas, 6 L.h-1. The
MRM transitions of hydroxybupropion were m/z 256→238 and 256→130; and those
of the hydroxy bupropion - d6 were 262 → 139 and 262 → 244. The assay was linear
from 0.001 to 10 uM (R2 < 0.99), precise (Coefficient of variation = 1-8%) and
accurate (94 - 105%).
For 6-hydroxy chlorzoxazone, optimal conditions for the multiple reaction monitoring
(MRM) scan in the negative ionization mode were: ion spray voltage, -4500 V; curtain
gas, 35 L/h; ion source Gas1, 55 L.h-1; ion source Gas2, 50 L.h-1; temperature, 450 oC;
collision Gas 6 L.h-1. The MRM transitions of 6-hydroxy chlorzoxazone were m/z
183.8→119.8 and 183.8→148.1; and those of 6-hydroxy chlorzoxazone-d2 were
187.6 → 121.9 and 187.6 → 149.8. The assay was also linear, precise and accurate.

3.2.5 Determination of in vitro kinetics of HBUP formation.
Following the determination of the concentration of HBUP in HLMs and HepaRG
cells, the rate of formation of HBUP was calculated. The in vitro kinetic parameters
of HBUP formation, km (apparent Michaelis-Menten constant), Vmax (the maximal
velocity) and CLint (intrinsic clearance), were estimated using GraphPad Prism
version 7.0 (GraphPad Software Inc., La Jolla, CA). The appropriateness of fit was
assessed by the sum of squares of residuals, and the standard errors of the parameter
estimates.
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3.2.6 PBPK Simulation
IVIVE of HBUP exposure after single and multiple doses of 150-mg oral bupropion in
obese volunteers were performed using Simcyp® simulator version 15.1.

The

demographic characteristics of donors Table 3.1 were used to match the donors of
livers with respect to age, BMI and gender.

The input parameters including

physicochemical properties of HBUP and CLint have been presented in Table 3.6.
All other parameters were set to the Simcyp default values of SV-bupropion
compound file. Bupropion was used as the substrate and the CYP2B6-mediated
formation of HBUP was added as the only metabolite. The other pathways leading to
the biotransformation of BUP to EB and TB were not included, hence changes in BUP
exposure was not reflective of BUP total clearance. Ten trials in 10 virtual subjects
were simulated and the overall means of Tmax, Cmax and AUC compared between
NoNAFLD and the NAFLD groups. The first order absorption model with a full
PBPK model was used to perform the simulations.

3.2.7 Statistical Analysis
Statistical analyses were carried out using SAS software version 9.3 (SAS Institute
Inc., Cary, NC) and graphs were generated using GraphPad Prism version 7.0. The
median together with the minimum and maximum values were expressed as: median
(minimum - maximum). Differences between groups were evaluated using MannWhitney U and Kruskal-Wallis tests for groups with two and greater than two
categories respectively. Both tests, which are nonparametric, were used because they
do not require the normality distribution assumption of data required by parametric
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approaches like T-test and ANOVA (analysis of variance). Statistical differences
were considered significant at the P < 0.05 level.

3.3 Results
3.3.1 Donor demographics and liver characterization.
Table 3.1 shows the demographics of 90 donors of the liver tissues, vendor-supplied
diabetic labels, results of the NAFLD characterization, and results of genotyping. The
median age and BMI were respectively 49 years and 31 kg.m-2 suggesting an obese
adult population.

The demographic distribution was approximately equal in all

categories of diabetes and NAFLD. Using generally accepted algorithms for NAFLD
classification (Kleiner et al., 2005, Kleiner and Makhlouf, 2016) the livers were
categorized into NoNAFLD (n=29), NAFL (n=34) and NASH (n=27).

The

NoNAFLD group was therefore designated as the control group. The NoNAFLD
group had steatosis level of < 5% in the hepatocytes and a median NAS score of 1,
compared with the NAFL and NASH groups with higher hepatic content of fat and > 1
median NAS score.
With the aid of our previously developed logistic model, the diabetic status of the
livers were confirmed: True nondiabetic (n = 36), True diabetic (n = 38), false
nondiabetic (n=8) and false diabetic (n=8). In all analyses where diabetic and nondiabetic groups were compared, the misclassified ones were excluded.
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3.3.2 Activity of CYP2B6 in HLM.
The rate of formation of HBUP was used as a probe to measure the activity of
CYP2B6. Though other pathways like the carbonyl reductase are involved in the
metabolism of BUP (Connarn et al., 2015), the formation of HBUP is mainly mediated
via the CYP2B6 pathway (Faucette et al., 2000, Hesse et al., 2000) and hence used for
phenotyping its activity. The activity of CYP2B6 in the 90 HLMs were determined at
10, 50, 100, 400, 800 and 1600 uM of bupropion. Initial analysis was however done
with the activity measures at 10, 100 and 400 uM bupropion in line with reported km
values Table 3.7. Activities were compared without the CYP2B6*5 and CYP2B6*6
variants. Though their impact on BUP disposition is not significant, this was done to
minimize confounding by their reduced in vitro activity and to balance the proportion
in the three NAFLD groups.
The activity of CYP2B6 was higher in the nondiabetic group compared with the
diabetic group.

Similarly, the false diabetic group had higher CYP2B6 activity

compared to the false nondiabetic group (Table 3.8). These differences were however
not significant. On the other hand, the activity was significantly different among the
NALD groups (p <0.01), with the NoNAFLD group having higher activity.
In the next step of the analyses, the HLMs with misclassified diabetes status were
removed to prevent them from confounding the analysis. Then the effect of NAFLD
was compared in the diabetic and nondiabetic groups (Table 3.9). Again, activity was
significant (p<0.03) among the NAFLD group. The trend of decrease in activity for
NAFLD was: NoNAFLD > NAFL > NASH in the nondiabetic group, but NoNAFLD
> NASH > NAFL in the diabetic group. Consequently, the highest activity was
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observed in the nondiabetic-NoNAFLD group and lowest was found in the diabeticNAFL group.

This suggested that the presence of diabetes could be a potential

aggravator of NAFLD and could confound the detection of the influence of NAFLD
on CYP2B6.

3.3.3 Kinetics of CYP2B6-mediated HBUP in HLMs.
The kinetics of HBUP in the HLMs were determined using the Michaelis-Menten
equation. The km, Vmax and CLint were estimated. Graphical inspection showed that
some of the HLMs did not attain saturable rates of HBUP formation as observed in
previous study(Faucette et al., 2000). Those HLMs had very high km values > 1000
uM. To improve the reliability of our analysis, a subset of the livers (Table 3.2) with
km ≤ 2x130 uM were compared (Faucette et al., 2000). The results of the kinetic
analysis (Table 3.3) showed that the Vmax decreased in the fashion:
NoNAFLD>NAFL>NASH;

whereas

the

km

increased

in

the

order:

NoNAFLD<NAFL<NASH. The decrease in Vmax was not statistically significant,
but the increase in km was (p<0.041). The CLint therefore was approximately 2-fold
lower in both NAFL and NASH groups.

3.3.4 mRNA Expression of CYP2B6, CAR and PXR in HLM.
The mRNA level of CYP2B6 decreased in the fashion: NoNAFLD > NAFL > NASH,
but was not statistically significant (Table 3.9).

The fold change in

NoNAFLD/NAFLD, did not correspond with the changes in the kinetic parameters.
Similarly, changes in mRNA of CAR and PXR did not correspond with changes in
CYP2B6 mRNA and kinetics.

This suggests that mRNA levels may not reflect
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CYP2B6 kinetic parameters adequately and may mislead the detection of the influence
of NAFLD on CYP2B6 if solely relied upon.

3.3.5 HepaRG Cell Lines.
In view of the heterogeneity of the HLMs, the HepaRG cell lines was used as a
homogenous system to confirm qualitatively and quantitatively the effect of fat
content on CYP2B6 expression and activity. Steatosis was induced in the HepaRG,
and the accumulation of fatty acids was confirmed using Oil Red O staining and UVspectrophotometry (Figure 3.1). The measurement of the Total AKT/Phospho AKT
(results not shown) showed a reduced insulin response in the FA-treated cells.
Because CYP2E1 enzyme expression and activity is elevated under steatotic
conditions (Chalasani et al., 2003, Aljomah et al., 2015), it was used as an endogenous
control to confirm induction of steatosis by monitoring the formation of 6hydroxychlorzoxazone (6-OH CZ).

In the FA-treated cells, the chlorzoxazone

hydroxylase activity was about 4-times higher compared to the control suggesting a
viable steatotic tool for further investigation.
Qualitatively consistent with the HLM data, the fatty-acid-loaded HepaRG cells
showed significantly lower activity compared to control (Figure 3.2). The Vmax was
47% lower in the FA-treated group. However, the km was 3.5-fold higher in the FAtreated.

Consequently, CLint was 5-fold lower in the FA-treated group.

Thus,

quantitatively, the HepaRG cells amplified the effect of steatosis in the HLMs.
Furthermore, the mRNA expression of CYP2B6, CAR and PXR were also
significantly reduced in fatty-acid-loaded HepaRG cells compared to control (results
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not shown).

3.3.6 Physiologically based pharmacokinetic (PBPK) Simulation.
The simulated exposure parameters of HBUP via CYP2B6 are presented in Table 3.4
and the concentration profiles in Figure 3.3. The Cmax was slightly higher in
NoNAFLD group compared to NAFL and NASH. AUC of HBUP was however
similar among groups.

Despite the limitations of our simulations (no NAFLD

population, no data on clearance of HBUP), the results show that a completely
different findings from our in vitro work is possible in complete human subjects.
Hence, clinical studies in human subjects would greatly enhance our understanding on
the influence of NAFLD on CYP2B6.

3.4 Discussion
CYP2B6 was originally considered an enzyme of minor significance.

However,

further investigations have shown that it plays both major and minor roles in the
metabolism of clinically relevant drugs. Bupropion is one of its major substrates.
Though

bupropion

is

metabolized

into

erythrohydrobupropion

(EB)

and

threohydrobupropion (TB) by carbonyl reductases, hydroxybupropion is the main
metabolite and it is formed via the CYP2B6 pathway (Faucette et al., 2000, Hesse et
al., 2000, Connarn et al., 2015). It is used in the treatment of depression and smoking
cessation, and to ensure safety and efficacy, various factors capable of influencing its
pharmacokinetics like gender, polymorphisms, renal impairment and alcoholic liver
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diseases (Turpeinen et al., 2007, DeVane et al., 1990, Ilic et al., 2013) have been
studied. Other groups have also studied the influence of NAFLD on the activity and
expression of CYP2B6 in human liver tissues. The aim of this study, however, was to
determine the influence of NAFLD on the activity of CYP2B6 and the in vitro kinetics
of HBUP formation. To our knowledge, this is the first report of the influence of
NAFLD on the in vitro kinetics of HBUP formation by CYP2B6.

In this work, we used two in vitro systems, Human Liver tissues and HepaRG cell
lines, to show that both Vmax and km of CYP2B6-mediated HBUP formation are
altered in NAFLD. In the HLMs, the presence of NAFLD caused a modest reduction
in the Vmax, but a significant increase in the km. Eventually, the CLint was about 2fold lower in the NASH group. Qualitatively, the findings in the HepaRG system was
similar to the HLM system, but alteration was more pronounced quantitatively. This
is not surprising as cell culture systems have the tendency to exaggerate effects.
Notwithstanding, our work is in agreement with another study in Sprague−Dawley rats
fed with a methionine/choline deficient (MCD) diet to induce NASH (Cho et al.,
2016). The in vitro kinetic parameters determined using the rat liver microsomes
showed 26 % reduction in Vmax and 2.4 fold increase in Km for the formation of
HBUP by Cyp2b1 (rat orthologue of human CYP2B6) in the NASH group.
Contrary to the findings in the HLMs, HepaRG, and the rat studies by Cho et al.,
2016, the differences in CLint between the NoNAFLD and the NAFLD groups did not
translate into differences in AUC except a slight decrease after simulating single and
multiple doses of 150-mg BUP. CLint is one of the parameters that could change in
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NAFLD. However, changes in the function and structure of the heart, kidneys and
other organs (Cassidy et al., 2015, Machado et al., 2012) may also influence the
overall disposition of a drug. Therefore, the combined effect of changes in the organs
and enzymatic activity are relevant to determine the overall disposition of BUP in
NAFLD. Our PBPK model attempted to do that, but we did not find enough data in
the literature to recapitulate NAFLD in the virtual population. This did not allow us to
account for possible changes in organs in NALF and NASH. Notwithstanding, our in
vitro findings highlight the potential of NALFD to alter CYP2B6-mediated HBUP
kinetics like ALD (Toshikuni et al., 2014, DeVane et al., 1990), which is similar to
NAFLD, but caused by significant alcohol consumption.
In addition to the above, our work shows that the heterogeneity of NAFLD and the
variableness of expression and activity of CYP2B6 may impair detection of the
influence of NAFLD on CYP2B6. Hence, the need to account for reasonable amount
of the variability in CYP2B6.

We accounted for diabetes because it is closely

associated with NAFLD (Anstee et al., 2013) and could potentially confound it.
HLMs showing non-saturable kinetics were excluded from analysis to prevent
confounding (Faucette et al., 2000).
This work had some limitations. Donors of HLMs were predominantly obese adults,
so we could not evaluate the influence of NAFLD in lean subjects. Secondly, we
could not account for all polymorphisms in our dataset, as this was impractical.
However, the high frequency variants with potential to alter in vitro kinetics were
removed. Lastly, we did not investigate the carbonyl reductase pathways for the
formation of EB and TB, hence, the CLint determined was more relevant to the
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CYP2B6-mediated formation of HBUP.
In summary, we investigated the effect of NAFLD on CYP2B6 using HLMs and
HepaRG cell lines. We observed that the Vmax was modestly reduced, and km
significantly increased, and CLint reduced in NAFL and NASH HLMs. Qualitatively,
the HepaRG findings corroborated the finding in the HLM in the NAFL group. This
investigation is hoped to contribute to our current knowledge on the influence of
NAFLD on CYP2B6-mediated HBUP in vitro kinetics; and offers some basis for
further studies in a clinical trials.
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3.6 Tables
Table 3.1 Demographic characteristics, diabetes status, liver biopsy grade.

Demographic characteristics, diabetes status, liver biopsy grade, and CYP2B6
genotypes of the donors of human liver tissues.

Variable

Category

Age
BMI

N/A
N/A
Female
Male
Caucasian
African American
Hispanics
Nondiabetic
Diabetic
Steatosis
Lobular
inflammation
Hepatocyte
ballooning
NAS score
*1*1
*1*5
*5*5
*1*1
*1*6
*6*6

Gender

Ethnicity

Diabetes

Liver
histology

CYP2B6*5

CYP2B6*6

NoNAFLD
(n=29)

NAFL
(n = 34)

NASH
(n = 27)

49 (21-78)
29 (19-89)
13 (14.4)
16 (17.8)
21 (23.3)
7 (7.8)
1 (1.1)
13 (14.4)
16 (17.8)
0 (0-0)

53.5 (33-56)
31 (17-70)
19 (21.1)
15 (16.7)
30 (33.3)
1 (1.1)
3 (3.3)
19 (21.1)
15 (16.7)
1.5 (1-3)

49 (33-74)
32 (22-52)
14 (15.6)
13 (14.4)
25 (27.8)
1 (1.1)
1 (1.1)
12 (13.3)
15 (16.7)
2 (1-3)

51 (21-78)
31 (17-89)
46 (51.1)
44 (48.9)
76 (84.4)
9 (10.0)
5 (5.6)
44 (48.9)
46 (51.1)
1 (0-3)

1 (0-2)

1 (0-2)

1 (1-3)

1 (0-3)

0 (0-1)

0 (0-2)

1 (1-2)

0 (0-2)

1 (0-3)
26 (28.9)
2 (2.2)
1 (1.1)
11 (12.2)
15 (16.7)
3 (3.3)

3 (1-5)
26 (28.9)
8 (8.9)
0
18 (20.0)
15 (16.7)
1 (1.1)

5 (3-7)
22 (24.4)
4 (4.4)
1 (1.1)
13 (14.4)
12 (13.3)
2 (2.2)

3 (0-7)
74 (82.2)
14 (15.6)
2 (2.2)
42 (46.7)
42 (46.7)
6 (6.7)

Overall
(n=90)

Data presented as median (minimum - maximum) or frequency (percentage of total
number of liver tissues). NAS, nonalcoholic fatty liver disease activity score. N/A, not
applicable.

126

Table 3.2 Demographic characteristics of a subset of donor livers.

Demographic characteristics of a subset of donor livers used to determine final in vitro
kinetic parameters (km, Vmax, CLint) of hydroxybupropion (HBUP) formation
CYP2B6-mediated hydroxylation of bupropion (BUP).
Variable

Category

NoNAFLD

NAFL

NASH

Age
BMI

NA
NA
Female
Male
Caucasian
African American
(AA)
Hispanics
Nondiabetic
Diabetic
Steatosis
Lobular inflammation
Hepatocyte ballooning
Fibrosis
NAS score

41 (28-62)
27 (19-50)
3 (27.27)
8 (72.73)
8 (72.73)

53 (36-69)
31 (17-37)
2 (28.57)
5 (71.43)
6 (85.71)

48 (39-68)
34 (26-50)
3 (42.86)
4 (57.14)
6 (85.71)

2 (18.18)*

0

0

1 (9.09)
3 (27.27)
8 (72.73)
0 (0-0)
1 (0-2)
0 (0-0)
1 (0-2)
1 (0-2)

1 (14.29)
5 (71.43)
2 (28.57)
1 (1-3)
1 (0-2)
0 (0-1)
1 (0-3)
3 (2-4)

1 (14.29)
2 ( 28.57)
5 (71.43)
2 (1-3)
1 (1-3)
1 (1-2)
0 (0-1)
4 (3-7)

Gender

Ethnicity

Diabetic

Liver
histology

*Only the NoNAFLD group had African Americans (AA). However, removing AA
did not alter the kinetics, maintained in the final analyses.
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Table 3.3 In vitro kinetic parameters of CYP2B6.

In vitro kinetic parameters of CYP2B6-mediated hydroxybupropion (HBUP) formation in human liver microsomes.
Values reported as median (min - max).

NAFLD Lesion

Vmaxa

Kmb*

Clintc

NoNAFLD (n=11)
NAFL (n=7)
NASH (n=7)

109.2 (26.41-350.8)
89.41 (22.97-349.8)
73.38 (18.17-172.4)

142.7 (66.38-240.2)
239.3 (128.2-247.7)
218.1 (160.9-244.2)

0.77
0.37
0.34

Fold Change in Clint
(NoNAFLD/NASH)
1
2.05
2.27
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* Kruskal Wallis , p-value <0.041; a, Vmax pmoles.min-1.mg microsomal protein-1; b, Km in units of micromolar
(uM); c, CLint = Vmax/km in units of uL.min-1.mg microsomal protein-1

Table 3.4 Simulated exposure parameters of hydroxybupropion.

Simulated exposure parameters of hydroxybupropion after single and multiple doses
of 150-mg oral bupropion using Simcyp simulator.
Dosing

Substrate

NoNAFLD
Single Hydroxybupropion NAFL
NASH
NoNAFLD
Multiple Hydroxybupropion NAFL
NASH

TMax (h)
4.32
5.53
6.03
5.50
8.25
8.25

CMax (mg/L)
0.10
0.09
0.09
0.19
0.18
0.18

AUC (mg/L.h)
2.79
2.68
2.67
6.52
6.74
6.78

The AUC0-inf was estimated for single doses; and AUC0-504 hrs for multiple doses.
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Figure 3.1 Lipid content of control and fatty acid (FA) loaded HepaRG cells.

Evaluation of the lipid content of control and fatty acid (FA) loaded HepaRG cells
(A and B) Oil Red O (ORO) staining. Intracellular lipid accumulation was not
observed in control (A). However, because the treatment group (B) was loaded with
palmitate and oleate (1:2), lipid accumulation was observed after ORO staining. (C)
Spectrophotometric assessment of intracellular lipid content (** TTest, p < 0.001).
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Figure 3.2 Representation of kinetic profile of CYP2B6.

Representation of kinetic profile of CYP2B6-mediated formation of hydroxybupropion:
Upper panel: In NoNALFD, NAFL and NASH human liver microsomes (HLMs). Lower panel: In control and steatotic HepaRG cell
lines.

Figure 3.3 Simulation of the plasma concentration time curve of HBUP.

Simulation of the plasma concentration time curve of Hydroxybupropion (HBUP) in
NoNAFLD, NAFL and NASH donors after administration of 150-mg of bupropion
single (upper graph) and multiple (lower graph) doses.
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3.7 Supplementary Information
Table 3.5 Sequences of primers for qRT-PCR
Gene

Forward primer

Reverse Primer

CYP2B6

ATGGGGCACTGAAAAAGACTGA

AGAGGCGGGGACACTGAATGAC

CAR

AGATGGAGCCCGTGTGGG

GGTAACTCCAGGTCGGTCAGG

PXR

GCTGACAGAGGAGCAGCGGATGA CCCTGGCAGCCGGAAATTCTT
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Table 3.6 PBPK input parameters.

Summary of parameters for simulating exposure of Hydroxybupropion (HBUP) after administering 150-mg of bupropion (BUP).
Category

Physicochemical
properties (BUP)
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Physicochemical
properties
(HBUP)

Parameter
Molecular weight
log P
Compound type
pKa
B/P
Molecular weight
log P
Compound type
pKa
B/P

Absorption

Absorption type

Distribution

Distribution model

Elimination
(Bupropion)
Elimination
(HBUP)

CYP2B6 CLint (nL.min-1.
mg microsomal protein-1)
CLiv (L/h)

NoNAFLD
239.74
3.4
monoprotic
base
8.02
0.82
255.74
2.22
monoprotic
base
7.65
0.55
First-order
absorption
model
Full PBPK
model

NAFL
239.74
3.4
monoprotic
base
8.02
0.82
255.74
2.22
monoprotic
base
7.65
0.55
First-order
absorption
model
Full PBPK
model

NASH
239.74
3.4
monoprotic
base
8.02
0.82
255.74
2.22
monoprotic
base
7.65
0.55
First-order
absorption
model
Full PBPK
model

Reference
Simcyp
Simcyp

770

370

340

Experimental

37.05

37.05

37.05

Simcyp**

Simcyp
Simcyp
Simcyp
Drugbank*
Drugbank*

Drugbank*
Simcyp Predicted

*Parameters were obtained from Drugbank: https://www.drugbank.ca/metabolites/DBMET00277 (accessed on 3/09/2018); ** Value obtained by dividing the
default Simcyp value (74.1 L/h) by 2. This was done to obtain half-life of approximately 20 hrs for HBUP

Table 3.7 Reported kinetics of CYP2B6.

Reported kinetics of CYP2B6-mediated formation of hydroxybupropion (HBUP) from
bupropion (BUP) in human liver microsomes (HLM).
No
1
2

N
HLM
HLM (n=105)

3
4
5

HLM
HLM (n=5)
HLM (n=4)

Vmax
105±3.4
53.3
(12.8 - 333.5)
131.2±5.8
739.5 ± 440.6
3623±1520

Km
198±18
73.4
(17.1-393.3)
87.9±20.2
130.2±22.0
89±14

n= number of human liver tissues used in study.
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Clint
0.53
0.77
(0.13-5.22)

Study
(Skarydova et al., 2014)
(Gao et al., 2017)

1.49
5.68
40.7

(Connarn et al., 2015)
(Faucette et al., 2000)
(Hesse et al., 2000)

Table 3.8 Summary of mRNA expression and activity of CYP2B6 (I)
A

CYPB6 activity (10 uM)

NonDiabetic (ND)
(n=31)
1.18 (0.2-45.85)

0.77 (0.27-30.2)

False nondiabetic
(n=6)
1.04 (0.28-8.16)

CYPB6 activity (100 uM)

6.49 (0.45-256.5)

4.41 (0.83-172)

CYPB6 activity (400 uM)
CYP2B6 mRNA
PXR mRNA
CAR mRNA
B

14.65 (1.19-459.5)
1.76 (0.04-58.15)
1.49 (0.23-7.74)
1.67 (0.03-4.61)

Variable
CYPB6 activity (10 uM)*
CYPB6 activity (100
uM)*
CYPB6 activity (400
uM)*
CYP2B6 mRNA
PXR mRNA
CAR mRNA

Variable
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1.01 (0.25-92.6)

Fold change
(ND/D)
1.53

6.24 (0.87-47.6)

6.69 (1.08-467.5)

1.47

9.98 (2.11-281)
0.52 (0.02-47.56)
1.36 (0.12-6.18)
1.67 (0.04-23.48)

13.85 (2.41-89.55)
0.26 (0.08-7.9)
1.89 (0.45-4.83)
1.3 (0.38-4.33)

17.3 (3.33-726)
0.3 (0.01-68.68)
1.1 (0.01-4.8)
1.22 (0.01-5.99)

1.47
3.38
1.10
1.00

NoNAFLD (n=24)

NAFL (n=32)

NASH (n=23)

1.78 (0.33-45.85)

0.6 (0.2-10.95)

0.92 (0.28-92.6)

Fold Change
(NoNAFLD/NASH)
1.93

11.62 (1.22-256.5)

3.41 (0.45-91.3)

5.62 (0.87-467.5)

2.07

27.93 (2.81-459.5)

7.33 (1.19-225)

12.65 (2.41-726)

2.21

1.36 (0.1-59.17)
1.53 (0.16-6.18)
1.98 (0.21-23.48)

0.63 (0.01-30.21)
1.41 (0.01-7.74)
1.94 (0.01-6.67)

0.45 (0.02-68.68)
1.09 (0.12-4.83)
1.11 (0.04-22.84)

3.02
1.40
1.78

Diabetic (D) (n=34)

A: The diabetic group was compared.
B: The NAFLD group was compared. * Kruskal Wallis, p-value <0.01;

False Diabetic (n=8)

Table 3.9 Summary of mRNA expression and activity of CYP2B6 (II).

Values reported as median (min - max). Summary statistics of overall levels of mRNA expression and activity of CYP2B6.
Values reported as median (min - max).

Diabetic
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Nondiabetic

Variable

NONAFLD (n=11/9)

NAFL (n =13/13)

NASH (n=10/9)

Fold Change
(NONAFLD/NASH)

CYPB6 activity (10 uM)*
CYPB6 activity (100 uM)*
CYPB6 activity (400 uM)*
CYP2B6 mRNA
PXR mRNA
CAR mRNA
CYPB6 activity (10 uM)*
CYPB6 activity (100 uM)*
CYPB6 activity (400 uM)
CYP2B6 mRNA
PXR mRNA
CAR mRNA

1.74 (0.33-30.2)
10.48 (1.22-172)
22.2 (2.81-281)
1.63 (0.12-47.56)
2.02 (0.16-6.18)
2.08 (0.46-23.48)
1.81 (0.36-45.85)
12.75 (1.93-256.5)
33.65 (4.28-459.5)
0.38 (0.1-58.15)
1.04 (0.23-3.84)
2.26 (0.21-4.61)

0.46 (0.27-2.38)
2.73 (0.83-15.7)
5.65 (2.11-32.75)
0.45 (0.03-7.98)
1.63 (0.29-2.78)
2.09 (0.24-6.67)
1.18 (0.2-10.95)
6.49 (0.45-91.3)
14.65 (1.19-225)
2.37 (0.05-30.21)
1.94 (0.61-7.74)
2.3 (0.03-4.31)

1.02 (0.33-9.66)
5.85 (1.72-66.7)
12.7 (6.39-122)
0.19 (0.02-4.02)
1.09 (0.12-2.5)
1.02 (0.04-22.84)
0.72 (0.41-6.22)
4.78 (1.74-37.7)
12.45 (4.44-69.55)
0.83 (0.04-5.41)
1.46 (0.3-2.41)
0.86 (0.29-3.63)

1.71
1.8
1.75
8.58
1.85
2.04
2.51
2.67
2.7
0.45
0.71
2.63

*Kruskal Wallis, p-value <0.03
The diabetic and NAFLD groups were simultaneously compared.

Table 3.10 Summary of mRNA expression and activity of CYP2B6

Summary of mRNA expression and activity of CYP2B6 in the subset of human liver
microsomes (HLM) used to determine the in vitro kinetics of CYP2B6-mediated
hydroxybupropion (HBUP) formation. Values reported as median (min - max).

Variable

NoNAFLD
(n=11)

NAFL (n=7)

NASH (n=7)

Fold Change
(NoNAFLD/NASH)

CYPB6 activity (10 uM)

7.89 (1.43-30.2)

4.28 (0.25-10.95)

3.59 (0.92-9.66)

2.20

CYPB6 activity (100 uM)

47.6 (8.99-172)

31.15 (1.08-91.3)

23.2 (5.11-66.7)

2.05

CYPB6 activity (400 uM)

89.55 (17.55-281)

64.35 (3.33-225)

45.85 (11.25-122)

1.95

CYP2B6 mRNA

3.15 (0.1-47.56)

2.37 (0.04-27.51)

0.11 (0.02-5.41)

28.64

PXR mRNA

0.86 (0.23-4.02)

1.86 (0.29-3.32)

1.49 (0.52-2.14)

0.58

CAR mRNA

1.65 (0.39-23.48)

2.62 (0.31-6.67)

1.36 (0.04-22.84)

1.21
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MANUSCRIPT IV

Abstract
Background and Objectives: PF-5190457 is an inverse agonist of the growth hormone
secretagogue receptor (hGHS-R1a), that is undergoing clinical trial for treatment of
alcohol use disorder.

The purpose of this study was to describe the population

pharmacokinetics (PK) of PF-5190457 and to identify clinical and demographic
characteristics that influence its PK variability.
Subjects and Methods. Data on drug dosage, sampling times and plasma
concentrations were collected retrospectively from two studies: Phase 1a and Phase
1b. Thirty five (35) healthy volunteers were enrolled in the Phase 1a, and 12 nontreatment seeking alcoholic subjects in the Phase 1b trial.

The log-transformed

concentration-time points were modeled in NONMEM. The influence of patients'
demographic and biochemical characteristics were evaluated; and the accuracy and
precision of the model parameters determined using bootstrapping. The predictive
performance of the final model was checked using percentile visual predictive check.
Results. The pharmacokinetics of PF-5190457 was best described by a onecompartmental model with first order absorption after oral administration.

The

estimated typical pharmacokinetic parameters included the absorption rate constant
(ka, 3.6 h-1), oral clearance (CL/F, 80 Lh-1) and apparent volume of distribution (V/F,
575 L).

Body weight and serum albumin on V/F reduced the interindividual

variability (IIV) associated with V/F by ~28%. Increasing body weight increased V/F,
whereas increasing serum albumin levels reduced it.
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Conclusion. PF-5190457 is rapidly cleared from the body. The V/F of PF-5190457 is
influenced by body weight and albumin. We anticipate that this model would serve as
a guide in designing dosage regimen for future clinical trials with PF-5190457.

Key words:
Albumin, Alcoholism, Clinical trial, Ghrelin, Growth Hormone, Pharmacokinetics,

Abbreviations:
ALT: alanine aminotransferase
AST: aspartate aminotransferase
AUDs: Alcohol Use Disorders
CL/F: oral clearance
CrCL: Creatinine clearance
CWRES: conditional weighted residuals
DSGRP: Dose group
DV: observed plasma concentration
GAM: generalized additive model
GH: growth hormone
GOAT: ghrelin O-acyl-transferase
hGHS-R1a: human growth hormone secretagogue receptor 1a
IIV: interindividual variability
IPRED: individual predicted concentration
IRB: Institutional Review Board
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ka: absorption rate constant
MDRD: modification of diet in renal disease
NCA: non-compartmental analysis
OFV: objective function value
PK: Pharmacokinetics
PRED: predicted plasma concentration
UPLC-MS/MS: UPLC/tandem mass spectrometry
V/F: apparent volume of distribution
VPC: visual predictive check
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4.1 Introduction
Alcohol Use Disorders (AUDs), i.e., alcohol abuse and alcohol dependence
(alcoholism) is a global concern [1, 2]. Despite its effects on health, economy and
society, only few medications are approved for treatment in both the United States
(US) and Europe. The available medications including naltrexone, disulfiram, and
acamprosate [3, 4] have not adequately met patients’ needs due to side effects and
moderate efficacy.

Consequently, there is a crucial need to identify novel

pharmacological targets to effectively treat AUDs.
Several drugs including sertraline [5, 6], topiramate [7-9] and baclofen [10, 11] are
under investigation for the treatment of AUD. More recently, the ghrelinergic system
(ghrelin receptor also known as growth hormone secretagogue receptor (hGHS-R1a),
ghrelin, and ghrelin O-acyl-transferase (GOAT)) is studied due to its involvement in
alcohol craving [12, 13] and offers a potential for the treatment of AUDs.
Ghrelin is a gastrointestinal peptide hormone produced mainly in the oxyntic glands of
the gastric fundus [14]. It serves as the endogenous agonist of the ghrelin receptor.
The activation of this receptor by ghrelin requires the acylation of its serine-3 residue
[15, 16] to acyl-ghrelin by GOAT. The physiological roles of the ghrelin system in
humans include stimulating the release of growth hormone (GH) [14], regulation of
food intake, body weight, adiposity, and glucose metabolism [17-19]. In view of its
roles, the ghrelinergic system is increasingly becoming an attractive pharmacological
target not only for the treatment of drug addiction [13, 20-22]; but also diabetes [23,
24], obesity [25], and Parkinson’s disease [26].
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PF-5190457, a spiro-azetidino piperidine compound, is an inverse agonist of hGHSR1a [27, 18]. Originally developed for the treatment of Type 2 diabetes and obesity,
PF-5190457 is being repurposed for the treatment of alcoholism. Due to its promising
pharmacological and safety profile, it has advanced into human clinical trials. To
maximize efficacy and minimize toxicity in subsequent phases of clinical trials of PF5190457, a thorough understanding of the clinical PK is essential. Therefore, the goal
of this work was to characterize the PK of PF-5190457 in healthy and non-treatment
seeking alcoholic subjects, and to investigate the covariates that influence PK
variability. We hope that the findings in this work will serve as a guide in designing
subsequent clinical trials in humans.

4.2 Methods
4.2.1 Study Design and Patients
Two Phase 1 studies, in healthy humans (Phase 1a) and in non-treatment seeking
alcoholic subjects (Phase 1b) were conducted by Pfizer and NIH at l’Hôpital Erasme
(Brussels, Belgium) and NIH Clinical Center (Bethesda, Maryland) respectively.
Institutional Review Board (IRB) approval was obtained prior to the beginning of each
study. All participants provided written informed consent before enrolment. Full
details of the Phase 1a study has been described previously [28]; whereas the Phase 1b
study has been accepted for publication (Manuscript 2017MP001300RR, Mol.
Psychiatry).
Phase 1a was a randomized, double-blind, placebo-controlled study of four cohorts of
single and divided doses of PF-5190457 or placebo: Cohorts 1 and 2 (9 subjects each)
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participated in a three-sequence crossover dose-escalation leg with doses of 2, 10, 50,
100, 300 mg and placebo substitution; Cohort 3 (8 subjects) underwent a standard
two-sequence crossover investigating gastric emptying after a single 150 mg dose or
placebo; and Cohort 4 (9 subjects) underwent a two-period, three-sequence incomplete
block receiving 40 or 300 mg divided dose regimens (with breakfast, 2 h post
breakfast, with dinner, and 2 h post dinner) [28]. In the dose-escalating, single-blind,
placebo-controlled, crossover Phase 1b study, 12 subjects received b.i.d doses of PF5190457 (placebo, 50 and 100 mg b.i.d) for 3 days. PF-5190457 was administered as
oral suspension in both studies.

4.2.2 Inclusion and Exclusion criteria for patient enrollment
A total of 47 adult subjects (age ≥ 18 years) with no clinically relevant abnormalities
identified in medical history, physical examinations, vital signs, electrocardiograms or
clinical laboratory tests were selected for both studies. Enrolled subjects in the Phase
1a study were healthy whereas those in Phase 1b were non-treatment seeking
alcoholics. Women enrolled in the studies were non-childbearing.

4.2.3 Data Collection
Patient data collected included demographics (e.g., age, race, sex, and body weight)
and

relevant

laboratory

findings

(e.g.,

alanine

aminotransferase,

aspartate

aminotransferase, serum albumin, serum creatinine, total bilirubin). Additional study
related characteristics like dose group (DSGRP), alcohol and nicotine use status of
subjects were included as covariates.

Creatinine clearance was determined from

serum creatinine using the MDRD (modification of diet in renal disease) equation [29]
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which accounts for racial and gender differences in serum creatinine levels.

4.2.4 PK sampling schedule and PF-5190457 Assay
Plasma concentration samples were collected up to 48 h (non-steady state PF-5190457
concentrations) for the Phase 1a study; and up to 73.5 h (Steady state PF-5190457
concentrations) from day 1 to 3 (immediately prior to dosing, 1-2 h. after dosing, and
approximately 30 mins after day 2) for Phase 1b. Each sample was quantified using a
validated UPLC/tandem mass spectrometry (UPLC-MS/MS) method described
previously. The limit of quantification of the two assays was 1 ng/mL [28, 30].

4.2.5 Population PK modeling
PopPK analysis of the concentration-time data of PF-5190457 was performed using
the computer program NONMEM (Version 7.3; ICON Development Solution, MD).
NONMEM allows the implementation of mixed effects (fixed and random) non-linear
regression models to estimate population means and variance of the population
pharmacokinetic parameters. PLTTOOLS (Version 5.5.1, San Francisco, CA) was
used as an interface throughout the entire modeling process and covariate selection;
while R (version 3.4.0) and R Studio (Version 1.0.153) were used for graphical
evaluations. A stepwise procedure was used to find the model that adequately fit the
data. Parameter estimation was done with first order conditional estimation with
interaction (FOCE -I).
analysis.

Natural logarithmic-transformed data were used for the

Both one-compartment (ADVAN2, TRANS2); and two-compartments

(ADVAN4, TRANS4) structural models with or without lag-time were explored.
Inter-individual variability was modeled using exponential error model:
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Pi = TVP*EXP(ETA(i)) ..................... (1);
Where Pi represents the parameter estimate of the ith subject, and TVP is the typical
parameter estimate in the population, and ETA(i) the random inter-individual
variability (IIV) in the parameter for the ith participant.
Residual variability was modeled using an additive proportional log error model:
$ERROR
PRED=F
IPRED=0
IF(F.GT.0) IPRED=LOG(F)
Yij = IPRED +SQRT(THETA(4)**2 + THETA(5)**2/F**2)*EPS(1)

Where Yij is the observed jth concentration in the ith subject; F is the model
prediction for jth concentration on the ith subject; and EPS(1) is the random residual
effect for the jth concentration; THETA(4) and THETA(5) are fixed effect additive
and proportional components of the error model respectively.

4.2.6 Covariate analysis
Candidate covariates presented in Table 4.1 were selected based on the trial design,
graphical inspection, significant change in OFV, changes in variance of IIV, and
physiological plausibility. The influence of covariates were conducted sequentially
using forward selection followed by backward elimination by comparing changes in
objective function value (OFV) of base and covariate models. Continuous covariates
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were centred to their median (med) values and modeled using additive (3),
multiplicative (4) and exponential (5) models in PLTTOOLS:
TVPi = ((THETA(i) + (THETA(x)-1) * (COV-medCOV)) * EXP(ETAi) ......(3)
TVPi = ((THETA(i) * (1+THETA(x)-1) * (COV-medCOV)) * EXP(ETAi) ...(4)
TVPi = ((THETA(i) * (COV/medCOV) * *(THETA(x)-1) * EXP(ETAi) .......(5)

Where COV is the covariate, medCOV is the median value of that covariate; and
x = 1 + (the number of THETAs in the $THETA block in the control stream).

4.2.7 Model Selection and evaluation
Comparison among the structural models as well as models containing covariates was
based on the OFV, goodness-of-fit plots, estimates of parameters, and visual
predictive checks. A p < 0.01, representing a decrease in OFV greater than 6.635 was
considered statistically significant (degrees of freedom = 1) for selection of a
structural model and covariates.

The basis of the critical values for model and

covariate selection is derived from the approximate χ2 distribution of the difference
between the OFV of two models.
The statistical significance and accuracy of the model parameters were assessed using
bootstrapping. Bootstrap datasets (n=1000, stratified by study population) were
generated by random sampling with replacement from the original dataset; and
parameters were estimated from each dataset. A 95 % confidence interval (2.5th and
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97.5th percentile) of each parameter distribution was then computed.
Finally, percentile visual predictive check (VPC) was conducted to examine adequacy
of the model in predicting the original data. We simulated 1000 replicates of the
original dataset, and compared the lower quartile, median and upper quartiles of the
observed and simulated data.

4.3 Results
4.3.1 Study Population
Forty-seven subjects were enrolled in both studies. All subjects in Phase 1a trial were
males (Caucasian = 90%); whereas in Phase 1b, 90 % were males (Black = 90%).
Body weight differed significantly between the two studies (t-test, p-value < 0.04), but
age did not. The demographic details of all subjects are summarized in Table 4.1.
Alcohol consumption per week and serum albumin concentration were significantly
higher in Phase 1b subjects (Mann Whitney, p <0.001).

There was no major

differences in the distribution of other laboratory tests Table 4.1 between study
subjects.

4.3.2 Pharmacokinetic Population Model
A total of 1354 data points were included in the analysis. A one-compartment model
with first-order absorption from the gastrointestinal tract adequately described the
data. Addition of a two-compartment model did not improve fit (increased OFV >
6.635). The overall model fitting to the data was satisfactory (r2=0.95, p-value <
0.001), as shown in Figure 4.1. The best-fit population PK parameter estimates and
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the bootstrap median (95 % confidence intervals) of the base model are shown in
Table 4.2. The oral clearance was ~80 Lhr-1, oral volume of distribution 575 L, and
t1/2 approximately 5 h. The inter-individual variability (IIV) of CL/F and Vd/F were
less than 30%.

The rate of absorption was however imprecise because few

concentration data points were available during the absorption phase of PF-5190457.

4.3.3 Covariate Analysis
The influence of each covariate on the PK parameters was tested. Based on the trial
design, the sex covariate was not considered though it appeared significant. This is
because the study population was predominantly males (~98 %). Also, since the
Phase 1a study was carried out in healthy subjects (who were predominantly white);
and Phase 1b in non-treatment seeking alcoholic subjects (who were predominantly
blacks), RACE was not considered as a potential covariate due to the possible
confounding by the differences in alcohol consumption by the two groups.
Graphical inspection and evaluation using a generalized additive model (GAM)
showed a significant association (p < 0.03) between interindividual variability (ETAs
of CL/F, V/F and Ka), body weight (WEIGHTKG) albumin (ALBUMIN) (Figure
4.2). In a univariate analysis, DSGRP on V/F significantly reduced the OFV (ΔOFV =
30) along with ALBUMIN and body WEIGHTKG (Supplementary Table 4.4 :
Table 4.6). Further evaluation of covariates resulted in no significant change in OFV
after addition of ALBUMIN and WEIGHTKG (on V/F) to the base model (with
DSGRP on V/F). The final covariate model based on forward selection was DSGRP,
ALBUMIN and WEIGHTKG on V/F. Backward elimination and examination of
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changes in IIV showed that a base model with ALBUMIN and WEIGHTKG on V/F
significantly reduced the OFV and the IIV associated with V/F by ~28% compared to
one containing DSGRP which changed OFV significantly, but reduced the IIV on V/F
by ~21% (Supplementary Table 4.7). In addition, since the covariates (WEIGHTKG
and ALBUMIN) were physiologically relevant to V/F, this model was selected as the
final covariate model and presented below (model 6):
V
WEIGHTKG
= THETA 2 ∗ +
F
78.3

0.85

+

ALBUMIN
4.32

−4.48

;……………….. 6

Where V/F is the apparent volume of distribution (L); THETA(2) is 279.53 L;
WEIGHTKG is body weight in kg; and ALBUMIN is serum albumin in g/dL. The
final PK parameters for the full model are presented in Table 4.3.
This model suggests that the typical value of V/F of a median weight (78.3 kg)
individual with median albumin level of 4.32 g/dL is 559 L. This value will increase
with increase body weight (when albumin is 4.32 g/L). On the other hand, the V/F
will decrease with increasing serum albumin levels (when body weight is 78.3 kg).

4.3.4 Model Evaluation
The goodness of fit plots for the base and full models are shown in Figure 4.1. The
plot of predicted (PRED) and observed (DV) shows symmetry of points about the line
of unit slope. The relative tightness of points was improved when individual predicted
values (IPRED) were plotted against DV.

The conditional weighted residuals

(CWRES) [31] were approximately distributed around CWRES=0, but showed a
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slight trend towards an additional compartment. Notwithstanding, the onecompartmental model was adequate for the model.
The median estimates and nonparametric 95 % CIs from the bootstrap analyses for
fixed effect and IIV parameters were in a 1:1 ratio indicating that the parameter
estimates in the final models were accurate, precise and statistically significant.
The results from the VPC evaluations Figure 4.3 suggested that there was good
agreement on the time course and central tendency (median) between distributions of
observed and simulated data. The lower quartile, median and upper quartile of the
observed concentration data were in agreement with the simulated data.

4.4 Discussion
PF-5190457 is an inverse agonist of the growth hormone secretagogue receptor
(hGHS-R1a), believed to reduce alcohol craving. The purpose of this study was to
describe the population pharmacokinetics of PF-5190457 and to identify clinical and
demographic patient characteristics that influence PK variability.
Two studies (Phase 1a and Phase 1b) have been conducted recently to characterize the
pharmacokinetics of PF-5190457 in healthy and alcoholic subjects separately [28]. In
both studies, non-compartmental analysis (NCA) was employed to estimate the
pharmacokinetic parameters.

NCA is relatively fast and does not require any

assumption of compartments. However, it has the tendency to under-estimate the
ascending absorption phase of the plasma-concentration time curve after oral
administration, or over-estimate the descending elimination phase, especially where
the sampling interval is larger than the half-life of the drug [32].
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Population

pharmacokinetics on the other hand, is model-based and is dependent on assumptions
that drugs move into hypothetical body compartments and permits the incorporation of
influential covariates on the PK parameters. PopPK is thus superior and used for
comprehensive characterization of the PK profile of a drug. To the best of our
knowledge, this is the first PopPK work for PF-5190457. This work presents an early
characterization of the PK profile of PF-5190457 using combined data from both
healthy and alcoholic subjects.
A one-compartment model with first-order absorption from the gastrointestinal tract
adequately described the data. Though the CWRES showed a slight trend towards an
additional compartment, a two-compartmental model did not improve the goodness of
fit. This is because the sampling interval between 57 and 72 h was large for the Phase
1b study, and introduced a pseudo compartment. The typical PopPK estimates of the
base model (CL/F, Vd/F, Ka and t1/2: 80 Lhr-1, 559 L, 3.7 hr-1 and 5 hrs respectively)
were in agreement with the bootstrap values; thus indicating the stability of the model
under 1000 bootstrap data sets.

The reported half-life from the previous works

however was higher (5.5 - 9.8 hrs) [28]. In NCA, the estimation of the half-life is
heavily dependent on 3-4 observations which determines the terminal slope.
Notwithstanding,

visual

inspections

of

the

concentration-time

curves

(Supplementary) shows that plasma concentration falls by 50 % approximately every
~5 hours. Overall, PF-5190457 is rapidly absorbed and rapidly cleared from the body,
supporting a washout period of 72 hrs for the removal of the parent drug from the
body during a crossover clinical trial.
We evaluated patient demographics (e.g., age, race, sex, and body weight) and
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relevant

laboratory

findings

(e.g.,

alanine

aminotransferase,

aspartate

aminotransferase, serum albumin, serum creatinine, total bilirubin) on the PKparameters.

Though initially many covariates came important; after further

optimization of the model, body weight (kg) and serum albumin (g/dL) remained
significantly important predictors on V/F. An increase in body weight will result in
increase in V/F; but an increase in serum albumin will decrease V/F. This implies
that, with oral clearance of ~80 Lh-1 and body weight of 78.3 kg, a subject with serum
albumin level of <3.5 gdL-1 (hypoalbuinemia) will have a V/F > 997 L and a t1/2 of >
8.6 hrs.

Thus, the V/F may change from 559 L to more than 990 L in

hypoalbuminemic subjects weighing 78.3 kg. In future trials and use of PF-5190457,
it may be necessary to dose subjects based on body weight and serum albumin levels;
and monitor patients for conditions that could alter serum albumin levels. This may be
more necessary in alcoholic individuals with alcoholic liver disease where serum
albumin level may be altered.
One limitation of this work was the absence of data points between 57 and 72 hrs for
the Phase 1b study. This resulted in a pseudo bi-exponential profile. Also, because the
studies were carried out in mainly males (98% of subjects), we could not evaluate the
differences in PK between males and females. Lastly, since the distribution of race
wasn't uniform in both studies, we could not evaluate the influence of race without
confounding from alcohol consumption.
Despite the limitations, our work provides the first PopPK characterization of PF5190457 and adequately shows that body weight and serum albumin are important
predictors of V/F. We anticipate that our model would serve as a guide in designing
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dosage regimen for participants of future clinical trials with PF-5190457.
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4.6 Tables
Table 4.1 Demographic and biochemical covariates of subjects

Characteristics
Sex (Male/Female)
Overall
Study 1
Study 2
Race(White/Black/Others)
Overall
Study 1
Study 2
Age (YEARS)
Overall
Study 1
Study 2
Weight (kg)
Overall
Study 1
Study 2
BMI (kg/m2)
Overall
Study 1
Study 2
ALT (IU/L)
Overall
Study 1
Study 2
ALBUMIN (g/dL)
Overall
Study 1
Study 2
AST (IU/L)
Overall
Study 1
Study 2
Serum Creatinine (mg/dL)

Subjects (N)

Median

Range

47
35
12

37
37
40

19-58
19-55
23-58

47
35
12

78.3
75.8
82.9

56.60-120.50
56.60-98.20
58.10-120.50

47
35
12

25.6
25.4
26.09

18.60 - 38.03
18.60 - 30.30
21.60 - 38.03

20.165
19.75
21.165

Jul-59
9.5 - 59
7 - 56.67

4.32
4.23
4.65

3.76 - 4.90
3.76 - 4.79
4.00 - 4.90

21.665
21
24.5

11.33 - 43
12.5 - 43
11.33 - 41

46/1
35/0
1-Nov
33/13/1
32/2/1
1/11/2000
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Overall
Study 1
Study 2
CRCL (mL/min)
Overall
Study 1
Study 2
Total Bilirubin (mg/dL)
Overall
Study 1
Study 2
Alcohol per week (Glass)
Overall
Study 1
Study 2
Nicotine Use
Overall
Study 1
Study 2
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0.9
0.88
0.945

0.53 - 1.2
0.68 - 1.18
0.53 - 1.20

125.528
130.761
119.884

73.97 - 246.64
76.15 - 172.27
73.97 - 246.63

0.64
0.7
0.515

0.27 - 1.55
0.3 - 1.55
0.27 - 1.03

5
3
65.8

0 - 136.60
0 - 12
37.87 - 136.36

1
1
2

0-6
1-6
0-6

Table 4.2 Population pharmacokinetic parameter estimates of the base model for PF5190457

Parameter

Estimate (Final Bootstrap:
Model)
median (95 % CI)

Fixed Effects
CL/F (L/hr)
V/F (L)
Ka (hr-1)
Theta(4); additive component
Theta(5); proportional component

79.53
575.00
3.62
0.31
0.56

79.80 (73.47 - 131.17)
577.00 (521.38 - 985.83)
3.65 (2.58 - 28.70)
0.31 (0.28 - 0.33)
0.56 (0.43 - 0.85)

Inter-individual Variability (IIV)
IIV CL/F, %
IIV V/F, %
IIV Ka, %

26.00
29.00
102.00

26.18 (18.46 - 54.78)
29.12 (18.96 - 67.74)
102.00 (74.11 - 454.78)

Residual Variability (Epsilon)
EPS (σ1), %

1, FIXED

CL/F, apparent clearance; V/F, apparent volume of distribution; Ka, absorption rate constant;
Theta(4), additive component of error model; Theta(5), proportional component of error
model weighting factor in the residual error; σ1is the residual error variability.
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Table 4.3 Population pharmacokinetic parameter estimates of the full model
(base+covariate) for PF-5190457

Parameter

Estimate (Final Bootstrap:
Model)
median (95 % CI)

Fixed Effects
CL/F (L/hr)
Theta(2)
Ka (hr-1)
Theta(4)
Theta(5)
Theta(6); on body weight (WT)
Theta(7); on serum albumin (ALB)

79.58
279.53
3.60
0.31
0.56
0.85
-4.48

80.00 (73.49 - 101.00)
280.77 (257.36 - 497.32)
3.66 (2.56 - 19.11)
0.31 (0.28 - 0.33)
0.56 (0.43 - 0.84)

Inter-individual Variability (IIV)
IIV CL/F, %
IIV V/F, %
IIV Ka, %

26.05
21.00
104.19

26.24 (18.42 - 67.34)
21.27 (13.37 - 82.21)
103.50 (76.13 - 192.38)

Residual Variability (Epsilon)
EPS (σ1), %

1, FIXED

Covariate model
V/F (L)

Theta(2)*[(WT/78.3)**0.85 + (ALB/4.32)**(-4.48)]

CL/F, apparent clearance; V/F, apparent volume of distribution; Ka, absorption rate
constant; Theta(4), additive component of error model; Theta(5), proportional
component of error model weighting factor in the residual error; σ1is the residual error
variability.
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4.7 Figures

Figure 4.1 Goodness of fit plots for base (top panel) and full model (bottom panel)
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Figure 4.2 Relationship between ETAs and covariates: Body weight (WEIGHTKG) and
serum albumin.
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Figure 4.3 Percentile visual predictive checks.

Percentile visual predictive checks for base (left hand side) and full (right hand side)
models. The lower quantile, median and upper quantile of observations (solid lines)
and simulations (dashed lines) of all data (top panel), data corresponding to 100 mg
dose in STUDY 1 (middle panel), and data corresponding to 100 mg dose in STUDY
2 (bottom panel).

167

4.8 Supplementary
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Figure 4.4 Graphs showing the plasma concentration-time plot of PF-5190457
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Figure 4.5 Graphs showing the relationship between ETAs and all covariates.
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Covariate selection (forward selection) based on change in OFV and
improvement in variance associated with interindividual variability.

Table 4.4 Step 2: Base model + single covariate
Covariate

Parameter

OF

ΔOF

CutOff OM-VAR1 OM-VAR2

BASE
DSGRP
DSGRP
ALBUMIN
ALBUMIN
STUDY
STUDY
STUDY
BMI
ALBUMIN
ALBUMIN
ALCOHOLPERWEEK
DSGRP
AGEYRS
WEIGHTKG
STUDY
STUDY
STUDY
DSGRP
ALCOHOLPERWEEK
CRCL_MDRD
AGEYRS
STUDY
STUDY
AGEYRS
WEIGHTKG
WEIGHTKG
TOTBILIRUB

V/F
ka
V/F
V/F
ka
ka
ka
ka
CL/F
CL/F
CL/F
V/F
V/F
V/F
CL/F
CL/F
CL/F
ka
V/F
ka
V/F
V/F
V/F
CL/F
CL/F
CL/F
V/F

-1071.89
-1101.93
-1086.79
-1085.55
-1085.55
-1081.23
-1081.23
-1081.23
-1080.99
-1080.09
-1080.09
-1080.05
-1079.45
-1079.43
-1079.33
-1078.45
-1078.45
-1078.45
-1078.38
-1077.91
-1077.88
-1076.34
-1076.34
-1076.34
-1076.20
-1075.98
-1075.98
-1075.85

0.00
30.04
14.90
13.66
13.66
9.34
9.34
9.34
9.10
8.20
8.20
8.16
7.56
7.54
7.44
6.56
6.56
6.56
6.49
6.02
5.99
4.45
4.45
4.45
4.31
4.10
4.10
3.96

> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63

0.069
0.068
0.068
0.069
0.069
0.067
0.067
0.067
0.055
0.055
0.055
0.057
0.069
0.068
0.068
0.059
0.059
0.059
0.068
0.069
0.068
0.068
0.069
0.069
0.062
0.062
0.062
0.068

0.084
0.087
0.084
0.063
0.063
0.087
0.087
0.087
0.085
0.085
0.085
0.084
0.086
0.071
0.071
0.084
0.084
0.084
0.083
0.072
0.085
0.075
0.076
0.076
0.084
0.084
0.084
0.085

OM-VAR3
1.046
1.051
0.872
1.103
1.103
0.693
0.693
0.693
1.040
1.040
1.040
1.050
1.051
1.012
1.012
1.054
1.054
1.054
0.869
1.069
1.103
1.044
1.067
1.067
1.047
1.047
1.047
1.066

Functional
Form

p-value

Exponential
Exponential
Multiplicative
Additive
Additive
Exponential
Multiplicative
Exponential
Additive
Multiplicative
Additive
Additive
Exponential
Additive
Exponential
Additive
Multiplicative
Additive
Additive
Multiplicative
Additive
Multiplicative
Additive
Exponential
Multiplicative
Additive
Exponential

0.00
0.00
0.000
0.000
0.002
0.00
0.002
0.00
0.004
0.004
0.004
0.006
0.01
0.006
0.01
0.010
0.010
0.011
0.014
0.014
0.035
0.035
0.035
0.04
0.043
0.043
0.05

OF is objective function; ΔOF is change in OF; OM-VAR variance associated with
CL/F (1), V/F (2), and Ka (3); DSGRP is dose group. Covariate was considered for the
next step of the analysis if p-value < 0.01.
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Table 4.5 Step 3. Base model + DSGRP on V/F + single covariate
Covariate
Base
ALBUMIN
WEIGHTKG
WEIGHTKG
ALBUMIN
ALBUMIN
ALCOHOLPERWEEK
DSGRP
WEIGHTKG
WEIGHTKG
ALCOHOLPERWEEK
DSGRP
ALCOHOLPERWEEK
ALBUMIN
ALBUMIN
ALBUMIN
WEIGHTKG
WEIGHTKG
DSGRP

Parameter
V/F
V/F
V/F
CL/F
CL/F
CL/F
CL/F
CL/F
CL/F
V/F
CL/F
CL/F
V/F
CL/F
V/F
V/F
CL/F
CL/F

OF

ΔOF

-1101.93
0.00
-1112.56 10.63
-1111.56
9.63
-1111.44
9.51
-1110.69
8.76
-1110.69
8.76
-1109.70
7.77
-1108.81
6.88
-1106.68
4.75
-1106.47
4.54
-1106.39
4.46
-1102.09
0.16
1166.90 -2268.83
-924.68 -177.25
-911.14 -190.78
-859.56 -242.37
-865.94 -235.99
-486.88 -615.05
-759.80 -342.13

Functional
P-value
form
1.051
Exponential
1.000
1.090
Additive
0.001
1.012
Exponential 0.002
1.011
Additive
0.002
1.048
Multiplicative 0.003
1.048
Additive
0.003
1.055
Additive
0.005
1.055
Exponential
0.009
1.050
Exponential
0.029
1.050
Additive
0.033
1.070
Additive
0.035
1.052
Additive
0.688
1.515
Multiplicative
20.458 Multiplicative
26.595
Exponential
39.615
Exponential
137.206 Multiplicative
620.837 Multiplicative
203346.000 Multiplicative

Cut off OM-VAR1 OM-VAR2 OM-VAR3
< 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63

0.068
0.069
0.068
0.068
0.055
0.055
0.057
0.069
0.062
0.062
0.069
0.069
0.072
0.109
0.106
0.112
0.038
0.003
0.039

0.087
0.067
0.070
0.070
0.088
0.088
0.088
0.088
0.087
0.087
0.078
0.087
0.284
0.798
1.636
1.303
0.130
4.543
0.642

OF is objective function; ΔOF is change in OF; OM-VAR variance associated with
CL/F (1), V/F (2), and Ka (3); DSGRP is dose group. Covariate was considered for the
next step of the analysis if p-value < 0.01.
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Table 4.6 Step 4. Base model + DSGRP on V/F + Body weight on V/F + single covariate
Covariate
Base
ALBUMIN
ALBUMIN
ALBUMIN
ALBUMIN
ALBUMIN
ALBUMIN
ALCOHOLPERWEEK
ALCOHOLPERWEEK
WEIGHTKG
WEIGHTKG
DSGRP
ALCOHOLPERWEEK
WEIGHTKG
DSGRP
DSGRP
ALCOHOLPERWEEK

Parmeter

OF

ΔOF

V/F
V/F
V/F
CL/F
CL/F
CL/F
CL/F
V/F
CL/F
CL/F
CL/F
CL/F
CL/F
CL/F
CL/F
V/F

-1102.6
-1124.8
-1123.3
-1123.3
-1111.5
-1110.7
-1110.7
-1110.4
-1109.8
-1107.5
-1107.2
-1103.2
-985.01
-984.83
-980.46
-979.76
-851.57

0
22.21
20.65
20.65
8.89
8.09
8.09
7.79
7.16
4.85
4.64
0.60
-117.61
-117.78
-122.15
-122.85
-251.04

Cutoff OM-VAR1 OM-VAR2 OM-VAR3
< 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
> 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63
< 6.63

0.068
0.067
0.067
0.067
0.055
0.055
0.055
0.056
0.068
0.061
0.061
0.067
0.053
0.054
0.062
0.062
0.504

0.072
0.043
0.045
0.045
0.073
0.073
0.073
0.073
0.060
0.071
0.071
0.072
0.081
0.078
0.079
0.080
0.125

1.035
1.085
1.094
1.094
1.032
1.031
1.031
1.038
1.059
1.035
1.036
1.035
1.131
1.145
1.148
1.150
4.051

Functional
Form
Exponential
Multiplicative
Additive
Exponential
Additive
Multiplicative
Additive
Additive
Exponential
Additive
Additive
Multiplicative
Multiplicative
Exponential
Multiplicative
Multiplicative

p-value
1
0.0000
0.0000
0.0000
0.0029
0.0044
0.0044
0.0052
0.0074
0.0276
0.0313
0.4391

OF is objective function; ΔOF is change in OF; OM-VAR variance associated with
CL/F (1), V/F (2), and Ka (3); DSGRP is dose group. Covariate was considered for the
next step of the analysis if p-value < 0.01.
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Covariate selection (backward elimination) based on change in OFV and
improvement in variance associated with interindividual variability of V/F
(ETA(2)).

Table 4.7 Backward elimination
Covariate
BASE MODEL
WEIGHT+ALBUMIN
DSGRP+WEIGHTKG
DSGRP+ALBUMIN
DSGRP+WEIGHTKG+ALBUMIN

OF
-1071.89
-1098.15
-1102.55
-1105.14
-1109.44

ΔOF
0
26.26
30.66
33.25
37.55

DF
0
2
2
2
3

IIV [ETA(2)]
29
21
27
25
23

p-value
> 0.0001
> 0.0001
> 0.0001
> 0.0001

WEIGHTKG is body weight in kg; DSGRP is dose group; IIV [ETA(2)] is
interindividual variability associated with volume of distribution (V/F).
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5

CONCLUSION

This work demonstrates the utility of in vitro drug metabolism and population
pharmacokinetics to elucidate the sources of pharmacokinetic variability.

In the first part of this work (Manuscripts I, II and III), we demonstrated that NAFLD
influences the in vitro kinetics of CYP2B6-mediated hydroxylation of bupropion. It
reduced the Vmax by ~32% and increased the km by ~2 fold. Consiquently, the
intrinsic clearance was reduced in NASH human liver microsomes (HLM) by 2.3 fold
compared to the NoNAFLD HLM. The HepaRG system, together with available
findings in Sprague-Dawley rats corroborrated the findings in the HLM. However, the
Simcyp simulation suggested a possibly different scenario in vivo. This may be due to
lack of an appropriate NAFLD population model for PBPK simulation. A wellcontrolled clinical trial may therefore be necessary to confirm the findings of this
study.
In the second part of this work (Manuscript IV), we used population pharmacokinetics
to characterize PF-5190457, and to identify potential covariates that influence the PK
variability of PF-5190457. A one-compartmental model with first order absorption
after oral administration best described the PK profile of PF-5190457. The estimated
typical PK parameters of the base model, including the absorption rate constant (3.6 h1

), oral clearance (79.53 Lh-1) and apparent volume of distribution (575 L), suggested

that PF-5190457 is rapidly absorbed and rapidly cleared from the body. Additionally,
body weight and serum albumin reduced the IIV associated with V/F by ~28%. Body
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weight and serum albumin were thus identified to be potential sources of PF-5190457
PK variability.
We believe this work presents new insights into the influence of NAFLD on CYP2B6mediated hydroxylation of bupropion. Similarly, it gives new information about the
PK of PF-5190457. It is hoped that the information will be useful for future studies
involving CYP2B6 and NAFLD. We also anticipate that our model for PF-5190457
would serve as a guide in designing future clinical trials with PF-5190457.
.

177

6

APPENDIX

6.1 NONMEM codes for Manuscript IV
BASE MODEL
;PF-05190457 was given as oral suspension
$PROBLEM 1CMT WITH ABSORPT PF-05190457 (BASE MODEL)
$DATA
C:/Users/ENOCH/Documents/4_PKPD_Model/step_5_final_models/DATAFILES/Fi
nalData_PK_COV_ALLSUBJ_V2_orem1a.csv IGNORE=C
$INPUT C SUBJID=DROP ID=PTID TIMEMNS=DROP TIME=TIMHRS ODV
DV=LNDV MDV CMT EVID AMT=AMTNG ADDL II DSGRP STUDY COHORT
CPEVENT ALBUMIN ALT AST SCr=DROP CRCL_CG=DROP CRCL_MDRD
TOTBILIRUB MALE1 AGEYRS WEIGHTKG BMI RACEW
ALCOHOLPERWEEK NICTINUSE
$SUBROUTINE ADVAN2 TRANS2
$PK
TVCL = THETA(1) ; specifying the clearance
CL = TVCL*EXP(ETA(1)); exponential IIV

TVV = THETA(2)
V = TVV*EXP(ETA(2)) exponential IIV
TVKA = THETA(3) ; specifying the absorption rate constant
KA = TVKA*EXP(ETA(3)) ; exponential IIV
S2=V ; scale paramenter of 1

$ERROR (OBSERVATIONS ONLY)
PRED=F
IPRED=0
IF(F.GT.0) IPRED=LOG(F)
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Y= IPRED +SQRT(THETA(4)**2 + THETA(5)**2/F**2)*EPS(1)

$THETA
(0.1,6000,);initial estimate for CL [CL]
(0.1,50000,); initial estimate for Vd [V]
(0.01,1,) ; initial estimate for KA [KA]
(0, 0.1);
(0, 0.1);
;(,0.01,);

$OMEGA 0.1 0.1 1; diagonal matrix for variance of omegas 1, 2, and 3
$SIGMA 1 FIX

$ESTIMATION
METHOD=1
SIGDIGITS=6

PRINT=1
POSTHOC

MAXEVALS=9999 NOABORT
INTER
MSFO=MSFO.OUTPUTFILE

$COVARIANCE
$TABLE ID EVID AMT TIME DSGRP STUDY IPRED CWRES NOPRINT
FILE=ALLRECORDS.TXT
$TABLE ID DSGRP STUDY CL V KA ETA1 ETA2 ETA3 FIRSTONLY
NOPRINT NOAPPEND FILE=FIRSTRECORDS.TXT

FULL MODEL (Base + Covariates)

;PF-05190457 was given as oral suspension
$PROBLEM 1CMT WITH ABSORPT PF-05190457 (Full model)
$DATA
C:/Users/ENOCH/Documents/4_PKPD_Model/step_5_final_models/DATAFILES/Fi
nalData_PK_COV_ALLSUBJ_V2_orem1a.csv IGNORE=C
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$INPUT C SUBJID=DROP ID=PTID TIMEMNS=DROP TIME=TIMHRS ODV
DV=LNDV MDV CMT EVID AMT=AMTNG ADDL II DSGRP STUDY COHORT
CPEVENT ALBUMIN ALT AST SCr=DROP CRCL_CG=DROP CRCL_MDRD
TOTBILIRUB MALE1 AGEYRS WEIGHTKG BMI RACEW
ALCOHOLPERWEEK NICTINUSE

$SUBROUTINE ADVAN2 TRANS2

$PK
TVCL = THETA(1) ; specifying the clearance
CL = TVCL*EXP(ETA(1)); exponential IIV
TVV = (THETA(2) * (WEIGHTKG / 78.3) ** (0.85)) + (THETA(2) * (ALBUMIN /
4.32) ** (-4.48))
V = TVV*EXP(ETA(2)) exponential IIV
TVKA = THETA(3) ; specifying the absorption rate constant
KA = TVKA*EXP(ETA(3)) ; exponential IIV
S2=V ; scale paramenter of 1
$ERROR (OBSERVATIONS ONLY)
PRED=F
IPRED=0
IF(F.GT.0) IPRED=LOG(F)
Y= IPRED +SQRT(THETA(4)**2 + THETA(5)**2/F**2)*EPS(1)

$THETA
(0.1,6000,);initial estimate for CL [CL]
(0.1,50000,); initial estimate for Vd [V]
(0.01,1,) ; initial estimate for KA [KA]
(0, 0.1);
(0, 0.1);

$OMEGA 0.1 0.1 1; diagonal matrix for variance of omegas 1, 2, and 3
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$SIGMA 1 FIX

$ESTIMATION
METHOD=1
SIGDIGITS=6

PRINT=1
POSTHOC

MAXEVALS=9999 NOABORT
INTER
MSFO=MSFO.OUTPUTFILE

$COVARIANCE
$TABLE ID EVID AMT TIME DSGRP STUDY IPRED CWRES NOPRINT
FILE=ALLRECORDS.TXT
$TABLE ID DSGRP STUDY CL V KA ETA1 ETA2 ETA3 FIRSTONLY
NOPRINT NOAPPEND FILE=FIRSTRECORDS.TXT
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